<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>BCSC1819_S12_C05_p091-120</title>
		<link href="BCSC1819_S12_C05_p091-120-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC1819_S12_C05_p091-120" lang="en-US">
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer000" class="_idGenObjectStyleOverride-1">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer001" class="_idGenObjectStyleOverride-1">
			</div>
		</div>
		<div id="_idContainer006" class="Basic-Text-Frame">
			<p class="chapter-number"><span class="cn-chap">CHAPTER</span><span class="cn-chap"> </span>5</p>
			<p class="chapter-title ParaOverride-1">Retinal Vascular Disease: Diabetic Retinopathy</p>
			<p class="activity-intro"><img class="_idGenObjectAttribute-1" src="data:image/png;base64,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" alt="" />&#9;<span class="italic">This chapter includes a related activity, which can be accessed by scanning the QR code provided in the text or going to </span><a href="http://www.aao.org/bcscactivity_section12"><span class="italic">www.aao.org/bcscactivity_section12</span></a><span class="italic">.</span></p>
			<p class="body-text--no-indent-">Diabetic retinopathy is a leading cause of vision loss worldwide among patients aged 25–74&#160;years, especially in developed countries such as the United States. This chapter provides a foundation for the evaluation and treatment of diabetic retinopathy.</p>
			<p class="h1 ParaOverride-2">Terminology and Classification</p>
			<div id="Chapt5_Top1">
			<p class="h2-h1">Diabetes Terminology</p>
			<p class="body-text--no-indent-">The terminology used for types of diabetes mellitus has evolved over the years. The American Diabetes Association (ADA) classifies diabetes mellitus as <span class="italic">type 1 diabetes mellitus,</span> formerly known as <span class="italic">insulin-&#173;dependent diabetes mellitus</span> (IDDM), and <span class="italic">type 2 diabetes mellitus,</span> formerly known as <span class="italic">non–&#173;insulin-&#173;dependent diabetes mellitus</span> (NIDDM). Type 1 diabetes mellitus results from the destruction of pancreatic <span class="greek">β</span>-&#173;cells, which usually leads to absolute insulin deficiency. This pro&#173;cess can be &#173;either idiopathic or immune-&#173;mediated. Type 2 diabetes mellitus is characterized by insulin re&#173;sis&#173;tance that may or may not be accompanied by insulin deficiency. The ADA also recognizes other forms of diabetes mellitus, including a genet&#173;ically mediated form secondary to endocrinopathy and drug-&#173; or chemical-&#173;induced diabetes mellitus.</p>
			<p class="h2 ParaOverride-3">Diabetic Retinopathy Terminology</p>
			<p class="body-text--no-indent-">Diabetic retinopathy is classified according to a severity scale based upon its clinical features. <span class="italic">In</span> <span class="italic">nonproliferative diabetic retinopathy</span> (NPDR), intraret&#173;i&#173;nal vascular changes are pres&#173;ent but &#173;there is no development of extraret&#173;i&#173;nal fibrovascular tissue; NPDR is staged across a spectrum of severity as mild, moderate, or severe. Although NPDR has been referred to as <span class="italic">background diabetic retinopathy,</span> this term is no longer recommended. The most advanced level of diabetic retinopathy, which can develop &#173;after an eye has progressed through the sequential stages of NPDR, is <span class="italic">proliferative diabetic retinopathy</span> (PDR). PDR is defined by the presence of ret&#173;i&#173;nal neovascularization resulting from diabetes-&#173;induced ischemia and is clinically staged as &#173;either early PDR or PDR with high-&#173;risk characteristics. <span class="italic">Diabetic macular edema</span> (DME), or swelling of the central ret&#173;ina, results from abnormal vascular permeability and can develop in patients with any severity level of diabetic retinopathy. DME is classified as <span class="italic">center-&#173;involved</span> (or <span class="italic">central-&#173;involved</span>) <span class="italic">DME</span> if the central 1&#160;mm–&#173;dia&#173;meter ret&#173;i&#173;nal subfield is thickened on optical coherence tomography (OCT); it is classified as <span class="italic">non–&#173;center-&#173;involved DME</span> if ret&#173;i&#173;nal thickening occurs only outside the central ret&#173;i&#173;nal subfield. <span class="italic">Clinically significant diabetic macular edema</span> (CSME) is an older definition for macular edema that meets certain severity criteria for size and location.</p>
			<p class="body-text">In the BCSC, study results are reported using the terminology of the par&#173;tic&#173;u&#173;lar study being described, even though such usage may not conform to current terminology.</p>
			</div>
			<p class="h1">Epidemiology of Diabetic Retinopathy</p>
			<div id="Chapt5_Top2">
			<p class="body-text--no-indent-">Diabetes mellitus is a growing global epidemic that is expected to affect 642 million individuals by the year 2040, leading to an associated increased prevalence of diabetic retin&#173;opathy worldwide. One-&#173;third of the global population of individuals with diabetes mellitus is estimated to have diabetic retinopathy; of that group, one-&#173;third is likely to have vision-&#173;threatening diabetic retinopathy.</p>
			<p class="body-text">An impor&#173;tant epidemiologic finding of the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) was the direct association of an increased prevalence of diabetic retinopathy with longer duration of diabetes mellitus in patients with both type 1 and type 2 diabetes mellitus. In the WESDR cohort, &#173;after 20&#160;years of diabetes mellitus, nearly 99% of patients with type 1 and 60% with type 2 disease demonstrated some degree of diabetic retinopathy. Proliferative diabetic retinopathy was found in 50% of type 1 patients who had 20&#160;years’ duration of disease and in 25% of type 2 patients who had 25&#160;years’ duration of disease. Furthermore, 3.6% of younger-&#173;onset patients (aged <span class="symbol">&lt;</span>30&#160;years at diagnosis) and 1.6% of older-&#173;onset patients (aged 30&#160;years or older at diagnosis) &#173;were found to have a visual acuity of 20/200 or worse. Such vision loss was attributable to diabetic retinopathy in 86% of the younger-&#173;onset patients and in 33% of the older-&#173;onset group.</p>
			<p class="body-text">WESDR epidemiologic data &#173;were based largely on white populations of northern &#173;Eu&#173;ro&#173;pean descent and therefore are not entirely applicable to other racial groups. According to the United States Centers for Disease Control and Prevention, in 2011, the age-&#173;adjusted percentage of adults with diagnosed diabetes mellitus who reported visual impairment was 20.7% for black participants, 17.1% for white participants, and 15.6% for Hispanic participants. Recent studies have suggested that rates of diabetic retinopathy progression and vision loss are lower in the modern era due to improvements in systemic control and treatment advances.</p>
			<p class="reference--non-journal--first ParaOverride-4">Centers for Disease Control and Prevention website. Diabetes Public Health Resource. Age-&#173;adjusted percentage of adults aged 18&#160;years or older with diagnosed diabetes reporting visual impairment, by race/ethnicity, United States, 1997–2011. Page last reviewed November&#160;19, 2013. Available at <a href="http://www.cdc.gov/diabetes/statistics/visual/fig5.htm"><span class="Hyperlink">www.cdc.gov/diabetes/statistics/visual/fig5.htm</span></a>. Accessed March 15, 2018.</p>
			<p class="reference--non-journal--mid">International Diabetes Federation website. Diabetes: Facts and figures. Available at <br /><a href="http://www.idf.org/about-diabetes/what-is-diabetes"><span class="Hyperlink">www.idf.org/about-diabetes/what-is-diabetes</span></a>. Accessed March 15, 2018.</p>
			<p class="reference--journal--mid">Klein R, Lee KE, Knudtson MD, Gangnon RE, Klein BE. Changes in visual impairment prevalence by period of diagnosis of diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. <span class="italic">Ophthalmology.</span> 2009;116(10):1937–1942.</p>
			<p class="reference--journal--mid">Yau JW, Rogers SL, Kawasaki R, et&#160;al; Meta-&#173;Analysis for Eye Disease (META-&#173;EYE) Study Group. Global prevalence and major risk &#173;factors of diabetic retinopathy. <span class="italic">Diabetes Care.</span> 2012;35(3):556–564.</p>
			</div>
			<p class="h1">Pathogenesis of Diabetic Retinopathy</p>
			<div id="Chapt5_Top3">
			<p class="body-text--no-indent-">Although the primary cause of diabetic microvascular disease remains poorly understood, exposure to hyperglycemia over an extended period results in biochemical and molecular pathway changes, including increases in inflammatory oxidative stress, advanced glycation end products, and protein kinase C pathways that ultimately cause endothelial damage and pericyte loss. Numerous hematologic abnormalities are also associated with the onset and progression of retinopathy, including increased platelet adhesion, increased erythrocyte aggregation, and defective fibrinolysis. However, the precise role of each of &#173;these abnormalities in the pathogenesis of retinopathy—&#173;individually or in combination—is not well defined.</p>
			<p class="body-text">Over time, ret&#173;i&#173;nal capillary changes such as basement membrane thickening and selective loss of pericytes lead to capillary occlusion and ret&#173;i&#173;nal nonperfusion. High-&#173;resolution imaging of the ret&#173;i&#173;nal vasculature, now available through OCT angiography (OCTA) and adaptive optics scanning &#173;laser ophthalmoscopy, often reveals areas of vascular remodeling even in eyes with clinically mild diabetic retinopathy. Vascular abnormalities occur in both the superficial and deeper ret&#173;i&#173;nal capillary plexuses. &#173;These changes worsen with increasing levels of diabetic retinopathy severity (<span class="xref-figure">Fig 5-</span>&#173;<span class="xref-figure">1</span>). In addition, endothelial barrier decompensation leads to serum leakage and ret&#173;i&#173;nal edema. In late stages of the disease, ret&#173;i&#173;nal neovascularization develops in response to increases in intraocular vascular endothelial growth &#173;factor (VEGF), which is produced by ischemic ret&#173;i&#173;nal tissue.</p>
			<p class="reference--journal--single">Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. <span class="italic">N Engl J Med.</span> 2012;366(13): <br />1227–1239.</p>
			</div>
			<p class="h1">Recommended Diabetes Mellitus–Related <br />Ophthalmic Examinations</p>
			<div id="Chapt5_Top4">
			<p class="body-text--no-indent-">In the first 5&#160;years following diagnosis of type 1 diabetes mellitus, retinopathy is rare. In contrast, at the time of their initial diagnosis of type 2 diabetes mellitus, a larger percentage of patients already have established retinopathy and require concomitant ophthalmic examination. &#173;Because pregnancy is associated with diabetic retinopathy progression, &#173;women with diabetes mellitus who become pregnant may require more frequent ret&#173;i&#173;nal evaluations. An eye examination is recommended in the first trimester and thereafter at the discretion of the ophthalmologist for all pregnant patients with diabetic retinopathy (<span class="xref-table">&#173;Table&#160;5-</span>&#173;<span class="xref-table">1</span>). Vision loss may occur from DME or from the complications of PDR. Although some regression of retinopathy may occur &#173;after delivery, photocoagulation treatment is generally recommended if high-&#173;risk PDR develops during or just before pregnancy. The frequency of follow-up visits depends on the severity of the retinopathy, history of blood glucose levels, and blood pressure control, as well as the threat to visual function from potentially missed opportunities to treat (<span class="xref-table">&#173;Table&#160;5-</span>&#173;<span class="xref-table">2</span>).</p>
			<p class="reference--journal--single">American Acad&#173;emy of Ophthalmology Ret&#173;i&#173;na/Vitreous Panel. Preferred Practice<span class="CharOverride-1">®</span> Pattern Guidelines. <span class="italic">Diabetic Retinopathy.</span> San Francisco: American Acad&#173;emy of Ophthalmology; 2016. Available at <a href="http://www.aao.org/ppp"><span class="Hyperlink">www.aao.org/ppp</span></a>.</p>
			</div>
			<p class="h1">Systemic Medical Management of Diabetic Retinopathy</p>
			<div id="Chapt5_Top5">
			<p class="body-text--no-indent-">Good glycemic control is by far the most impor&#173;tant &#173;factor in the medical management of diabetic retinopathy, as demonstrated by both the Diabetes Control and Complications Trial (DCCT; <span class="xref-sidebar">Clinical Trial 5-</span>&#173;<span class="xref-sidebar">1</span>) and the United Kingdom Prospective Diabetes Study (UKPDS; <span class="xref-sidebar">Clinical Trial 5-</span>&#173;<span class="xref-sidebar">2</span>). In &#173;these studies, intensive glycemic control was associated with a reduced risk of a new onset of retinopathy and with reduced progression of existing retinopathy in &#173;people with diabetes mellitus (type 1&#160;in the DCCT and type&#160;2 in the UKPDS). In addition, the DCCT demonstrated that intensive glycemic control (compared with conventional treatment) was associated with reductions in progression to severe NPDR and PDR, incidence of DME, and need for panret&#173;i&#173;nal and focal photocoagulation. Even small changes in sustained hemoglobin A<span class="subscript _idGenCharOverride-1">1c</span> (HbA<span class="subscript _idGenCharOverride-1">1c </span><span class="subscript">)</span> levels &#173;were found to have a large impact on diabetic retinopathy progression. Indeed, when compared to standard glycemic control, intensive glycemic control was associated with decreases in retinopathy onset, progression of retinopathy, and need for ocular surgery over at least 2 subsequent de&#173;cades, even &#173;after the DCCT study ended and the HbA<span class="subscript _idGenCharOverride-1">1c</span> levels between the original randomization groups converged. This “metabolic memory” phenomenon implies sustained benefit from early intensive glycemic control. Based on the DCCT and UKPDS results, most patients with diabetes are now recommended to achieve an HbA<span class="subscript _idGenCharOverride-1">1c</span> level of <span class="symbol">&lt;</span>7.0%. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial and its follow-up (ACCORDION) study demonstrated a benefit for further reduction in HbA<span class="subscript _idGenCharOverride-1">1c</span> levels down to <span class="symbol">&lt;</span>6.0% for slowed diabetic retinopathy progression in patients with type 2 diabetes mellitus; however, this intensive regimen is not generally recommended &#173;because it was also associated with greater mortality rate.</p>
			<p class="body-text"><span class="italic">Hypertension,</span> when poorly controlled over many years, is associated with a higher risk of progression of diabetic retinopathy and DME. The UKPDS showed that control of hypertension was also beneficial in reducing progression of retinopathy and vision loss. <span class="italic">Severe carotid artery occlusive disease</span> may result in advanced PDR as part of ocular isch&#173;e&#173;mic syndrome. <span class="italic">Advanced diabetic nephropathy</span> and <span class="italic">anemia</span> may also exacerbate diabetic retinopathy. Abnormally high <span class="italic">lipid levels</span> are associated with greater risk of vision loss from DME-&#173;associated hard exudates.</p>
			<p class="reference--journal--first">Aiello LP, Sun W, Das A, Gangaputra S, et&#160;al; DCCT/EDIC Research Group. Intensive diabetes therapy and ocular surgery in type 1 diabetes. <span class="italic">N Engl J Med.</span> 2015;372(18):1722–1733.</p>
			<p class="reference--journal--mid">Chew EY, Ambrosius WT, Davis MD, et&#160;al; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. <span class="italic">N Engl J&#160;Med.</span> 2010;363(3):233–244.</p>
			<p class="reference--journal--mid">Chew EY, Mills JL, Metzger BE, et&#160;al. Metabolic control and progression of retinopathy: The Diabetes in Early Pregnancy Study. National Institute of Child Health and &#173;Human Development Diabetes in Early Pregnancy Study. <span class="italic">Diabetes Care.</span> 1995;18(5):631–637.</p>
			<p class="reference--journal--mid">Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. <span class="italic">Ophthalmology.</span> 1995;102(4):647–661.</p>
			<p class="reference--journal--mid">Nathan DM, Genuth S, Lachin J, et&#160;al; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-&#173;term complications in insulin-&#173;dependent diabetes mellitus. <span class="italic">N Engl J Med.</span> 1993;<br />329(14):977–986.</p>
			<p class="reference--journal--mid">UK Prospective Diabetes Study Group. Intensive blood-&#173;glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). <span class="italic">Lancet.</span> 1998;352(9131):837–853.</p>
			<p class="reference--journal--mid ParaOverride-5">UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. <span class="italic">BMJ.</span> 1998;317(7160):703–713.</p>
			</div>
			<p class="h1 ParaOverride-6">Abnormalities Associated With Vision Loss <br />From Diabetic Retinopathy</p>
			<div id="Chapt5_Top6">
			<p class="body-text--no-indent-">Vision loss in patients with diabetic retinopathy is commonly associated with the following abnormalities:</p>
			<ul>
				<li class="bullet-list-first">capillary leakage (DME)</li>
				<li class="bullet-list-mid">capillary occlusion (macular ischemia)</li>
				<li class="bullet-list-mid">sequelae from ret&#173;i&#173;nal ischemia (ret&#173;i&#173;nal neovascularization, vitreous hemorrhage, tractional ret&#173;i&#173;nal detachment, neovascular glaucoma)</li>
			</ul>
			</div>
			<p class="h1 ParaOverride-6">Nonproliferative Diabetic Retinopathy</p>
			<div id="Chapt5_Top7">
			<p class="body-text--no-indent-">Ret&#173;i&#173;nal microvascular changes that occur in NPDR are limited to the ret&#173;ina and do not extend beyond the internal limiting membrane (ILM). Characteristic findings in NPDR include intraret&#173;i&#173;nal hemorrhages, microaneurysms, cotton-&#173;wool spots, intraret&#173;i&#173;nal micro&#173;vascular abnormalities (IRMAs), and dilation and beading of ret&#173;i&#173;nal veins. The NPDR severity level (mild, moderate, severe) is graded based on the extent and severity of &#173;these findings as compared to standard photo&#173;graphs from the Early Treatment Diabetic Retinopathy Study (ETDRS). Rates of progression to more advanced disease are higher with increased baseline ETDRS retinopathy severity levels.</p>
			<p class="body-text">To help clinicians identify &#173;those patients at greatest risk of progression to PDR and high-&#173;risk PDR, the ETDRS investigators developed the 4:2:1 rule, which is largely based on results from the ETDRS Report Number 9 (<span class="xref-sidebar">Clinical Trial 5-3</span>). A case of severe NPDR was defined as having any 1 of the following features:</p>
			<ul>
				<li class="bullet-list-first ParaOverride-7">severe intraret&#173;i&#173;nal hemorrhages and microaneurysms in <span class="italic">4</span> quadrants (<span class="xref-figure">Fig 5-2</span>)</li>
				<li class="bullet-list-mid">definite venous beading in <span class="italic">2</span> or more quadrants (<span class="xref-figure">Fig 5-3</span>)</li>
				<li class="bullet-list-last ParaOverride-8">moderate IRMA in <span class="italic">1</span> or more quadrants (<span class="xref-figure">Fig 5-4</span>)</li>
			</ul>
			<p class="body-text--no-indent-">In the ETDRS, patients with severe NPDR &#173;were found to have a 15% and 60% chance of progression to high-&#173;risk PDR within 1 and 3&#160;years, respectively. Very severe NPDR, which was defined as having 2 or more of the features in the preceding list, increased the chance of progression to high-&#173;risk PDR within 1 year to 45%.</p>
			<p class="body-text">The ETDRS scale for classification of diabetic retinopathy severity level has been considered the gold-&#173;standard method for several de&#173;cades. To employ it, clinicians need to acquire and interpret standardized photographic fields that cover approximately 90° of the posterior ret&#173;ina. With ultra-&#173;wide-&#173;field imaging, over 80% of the ret&#173;ina can now be visualized in a single 200° image. Peripheral diabetic retinopathy lesions are often pres&#173;ent outside of the standard ETDRS fields; &#173;these suggest greater diabetic retinopathy severity in nearly 10% of eyes. Preliminary studies suggest that predominantly peripheral diabetic retinopathy lesions may be associated with greater risk of subsequent diabetic retino&#173;pathy progression. This association is being evaluated in the ongoing Diabetic Retino&#173;pathy Clinical Research Network (<a href="http://DRCR.net">DRCR.net</a>) Protocol AA.</p>
			<p class="body-text">Ret&#173;i&#173;nal capillary nonperfusion is a common finding in diabetic retinopathy, especially in more advanced levels of severity. Closure of ret&#173;i&#173;nal arterioles may result in larger areas of nonperfusion and progressive ischemia. The foveal avascular zone may appear increasingly irregular on fluorescein angiography (FA) or OCTA and enlarged as the innermost capillaries become nonperfused. Peripheral nonperfusion is frequently seen on ultra-&#173;wide-&#173;field FA, even in eyes with mild NPDR.</p>
			<p class="body-text">Patients with NPDR can lose visual function through 2 mechanisms: (1) increased intraret&#173;i&#173;nal vascular permeability, resulting in macular edema (see the section Diabetic Macular Edema, &#173;later in this chapter), and (2) variable degrees of intraret&#173;i&#173;nal capillary closure, resulting in macular ischemia.</p>
			<p class="reference--journal--first ParaOverride-9">Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation <br />for diabetic retinopathy. ETDRS report number 9. <span class="italic">Ophthalmology.</span> 1991;98(5 suppl):<br />766–785.</p>
			<p class="reference--journal--mid">Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photo&#173;graphs—an extension of the modified Airlie <br />House classification. ETDRS report number 10. <span class="italic">Ophthalmology</span>. 1991;98(5 Suppl):<br />786–806.</p>
			<p class="reference--journal--mid">Silva PS, Cavallerano JD, Haddad NM, et&#160;al. Peripheral lesions identified on ultrawide field imaging predict increased risk of diabetic retinopathy progression over 4&#160;years. <span class="italic">Ophthalmology</span>. 2015;122(5):949–956.</p>
			<p class="h2 ParaOverride-10">Treatment of Nonproliferative Diabetic Retinopathy</p>
			<p class="body-text--no-indent-">Aside from systemic control of blood glucose, lipids, and hypertension, &#173;there is no clear treatment mandate for eyes with NPDR without DME. Early treatment with panret&#173;i&#173;nal photocoagulation should be considered for patients with severe NPDR or worse, especially if the patient has type 2 diabetes or is likely to be nonadherent to recommendations for follow-up or systemic control. In addition, anti-&#173;VEGF therapy given for DME has been shown to substantially improve diabetic retinopathy severity in eyes at all severity levels of NPDR. &#173;After 2&#160;years of continuous, monthly treatment with an anti-&#173;VEGF drug, nearly 40% of eyes &#173;will improve by 2 or more levels on the ETDRS diabetic retinopathy severity scale. Although ranibizumab is FDA-&#173;approved for use in diabetic retinopathy, including NPDR without DME, large-&#173;scale randomized controlled &#173;trials to evaluate the efficacy and safety of anti-&#173;VEGF treatments in eyes with moderate to severe NPDR without DME are currently ongoing.</p>
			<p class="body-text">Intravitreal ste&#173;roid therapy for DME has also been shown to improve diabetic retinopathy severity level. The ACCORD and Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studies demonstrated reductions in diabetic retinopathy progression &#173;after fenofibrate treatment in patients with type 2 diabetes through mechanisms that are likely in&#173;de&#173;pen&#173;dent of fenofibrate’s effects on blood lipid levels. Fi&#173;nally, it has been hypothesized that creation of a posterior vitreous detachment might improve outcomes in diabetic eyes at risk of developing PDR &#173;because the vitreous scaffolding that enables extraret&#173;i&#173;nal neovascular proliferation is removed. However, currently &#173;there is no role for surgery in the management of NPDR.</p>
			<p class="reference--journal--first ParaOverride-4">ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, et&#160;al. Effects of medical therapies on retinopathy progression in type 2 diabetes. <span class="italic">N Engl J Med.</span> 2010;363(3):233–244.</p>
			<p class="reference--journal--mid">Bressler SB, Qin H, Melia M, et&#160;al; Diabetic Retinopathy Clinical Research Network. Exploratory analy&#173;sis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. <span class="italic">JAMA Ophthalmol</span>. 2013;131(8):1033–1040.</p>
			<p class="reference--journal--mid">Ferris&#160;F. Early photocoagulation in patients with &#173;either type I or type II diabetes. <span class="italic">Trans Am Ophthalmol Soc</span>. 1996;94:505–537.</p>
			<p class="reference--journal--mid">Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-&#173;term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk &#173;factors for worsening retinopathy. <span class="italic">Ophthalmology</span>. 2015;122(2):367–374.</p>
			</div>
			<p class="h1 ParaOverride-11">Proliferative Diabetic Retinopathy</p>
			<div id="Chapt5_Top8">
			<p class="body-text--no-indent-">As retinopathy progresses, capillary damage and nonperfusion increase. Worsening ret&#173;i&#173;nal ischemia leads to release of vasoproliferative &#173;factors and the subsequent development of ret&#173;i&#173;nal neovascularization. VEGF is 1 of the major proangiogenic &#173;factors isolated from the vitreous of patients with PDR. This &#173;factor can stimulate neovascularization of the ret&#173;ina, optic nerve head, or anterior segment.</p>
			<p class="body-text">Extraret&#173;i&#173;nal fibrovascular proliferation, which defines PDR, progresses through 3 stages:</p>
			<p class="numbered-list-first">1.&#9;Fine new vessels with minimal fibrous tissue cross and extend beyond the ILM, often using the posterior hyaloid as a scaffold.</p>
			<p class="numbered-list-mid">2.&#9;The new vessels increase in size and extent, developing an increased fibrous component.</p>
			<p class="numbered-list-last">3.&#9;The new vessels regress, leaving residual fibrovascular tissue that may be tethered within the posterior hyaloid.</p>
			<p class="body-text">Neovascular proliferation is categorized by its location: &#173;either on or within a disc dia&#173;meter of the disc (NVD, neovascularization of the disc) or elsewhere (NVE, neovascularization elsewhere).</p>
			<p class="body-text">Patients may receive treatment at any stage of PDR; however, treatment is usually considered mandatory once an eye has developed high-&#173;risk characteristics. PDR with high-&#173;risk characteristics is defined as having any of the following findings:</p>
			<ul>
				<li class="bullet-list-first">any NVD with vitreous or preret&#173;i&#173;nal hemorrhage</li>
				<li class="bullet-list-mid">extent of NVD <span class="italic">greater than or equal to</span> one-&#173;fourth disc area, with or without vitreous or preret&#173;i&#173;nal hemorrhage (<span class="symbol">≥</span> ETDRS standard photo&#173;graph 10A) (<span class="xref-figure">Fig 5-&#173;5</span>)</li>
				<li class="bullet-list-last">extent of NVE <span class="italic">greater than or equal to</span> one-&#173;half disc area, with vitreous or preret&#173;i&#173;nal hemorrhage (<span class="xref-figure">Fig 5-</span>&#173;<span class="xref-figure">6</span>)</li>
			</ul>
			<p class="body-text--no-indent-">Treatment may be deferred in eyes that have not developed high-&#173;risk characteristics or in eyes that have peripheral neovascularization outside the 7 standard ETDRS fields without accompanying hemorrhage; &#173;these cases can be watched closely &#173;until the PDR worsens. However, eyes at especially high risk for diabetic retinopathy progression due to patient nonadherence or poor systemic control should be treated promptly.</p>
			<p class="h2 ParaOverride-12">Management of Proliferative Diabetic Retinopathy and Its Complications</p>
			<p class="body-text--no-indent-">The goal of management of PDR is to control ischemia and reduce ocular VEGF levels so that neovascularization can involute or regress. This management can be accomplished with intravitreal administration of anti-&#173;VEGF drugs or with ablation of ischemic ret&#173;ina via &#173;laser photocoagulation. &#173;Because of the contraction of fibrovascular tissue, treatment may be followed by increased vitreoret&#173;i&#173;nal traction, recurring vitreous hemorrhage, tractional ret&#173;i&#173;nal detachment, and/or combined tractional and rhegmatogenous ret&#173;i&#173;nal detachment. Complications from PDR or its treatment—&#173;vitreous hemorrhage and tractional ret&#173;i&#173;nal detachment—&#173;can be addressed with vitreoret&#173;i&#173;nal surgical interventions, when appropriate.</p>
			<p class="h3 ParaOverride-13">Nonsurgical management of proliferative diabetic retinopathy</p>
			<p class="h4-text-h3"><span class="h4-head">Anti-&#173;VEGF and ste&#173;roid drugs</span> Multiple studies, including phase 3 &#173;trials of anti-&#173;VEGF drugs for the treatment of DME, have demonstrated that intravitreal administration (see the section Intravitreal Injections in Chapter&#160;20 of this volume for a discussion of the injection procedure) of anti-&#173;VEGF drugs is highly effective at regressing ret&#173;i&#173;nal neovascularization in eyes with PDR. Anti-&#173;VEGF therapy leads to regression of diabetic neovascular complexes in both newly diagnosed cases and chronic, refractory disease. Potential complications from the use of anti-&#173;VEGF drugs in the management of PDR include tractional ret&#173;i&#173;nal detachments, ret&#173;i&#173;nal tears, and combined tractional and rhegmatogenous ret&#173;i&#173;nal detachments that are related to the induced rapid contracture of the fibrovascular tissue.</p>
			<p class="body-text">&#173;Because of its effectiveness in regressing intraocular neovascularization and its generally favorable safety profile, anti-&#173;VEGF therapy is a reasonable first-&#173;line treatment alternative to panret&#173;i&#173;nal photocoagulation (PRP) for many eyes with PDR. The <a href="http://DRCR.net">DRCR.net</a> Protocol S study randomized eyes with active PDR to treatment with &#173;either standard-&#173;care prompt PRP or intravitreal ranibizumab and deferred PRP. At 2&#160;years, visual outcomes &#173;were equivalent between the PRP and anti-&#173;VEGF treated groups. However, ranibizumab treatment was associated with multiple benefits over PRP, including better average vision over the 2&#160;years, reductions in peripheral visual field loss, reduced rates of vitrectomy surgery, and fewer cases of DME onset. Ranibizumab was well tolerated; no substantial differences in rates of major cardiovascular adverse events &#173;were found between the treatment groups. Longer-&#173;term follow-up through the full 5-&#173;year study duration &#173;will determine &#173;whether anti-&#173;VEGF treatment burden decreases over time and &#173;whether the anti-&#173;VEGF effect endures &#173;after treatments are halted. (For more on <a href="http://DRCR.net">DRCR.&#173;net</a> studies, see the sidebar Selected Diabetic Retinopathy Clinical Research Network Studies at the end of this chapter.)</p>
			<p class="body-text">Although ranibizumab is effective for PDR treatment and offers some advantages over PRP, &#173;whether to use anti-&#173;VEGF versus PRP should be based on individual patient circumstances. Patients receiving anti-&#173;VEGF need to be able to adhere to near monthly follow-up visits throughout the first 1–2&#160;years of treatment. For patients who have a high likelihood of nonadherence due to medical instability or other limitations, treatment with PRP is the most appropriate option.</p>
			<p class="body-text">Anti-&#173;VEGF drugs also cause involution of anterior segment neovascularization and have been successfully used to treat neovascular glaucoma. In addition, when administered preoperatively, &#173;these drugs may be helpful as an adjunct to vitrectomy to manage complications of PDR.</p>
			<p class="body-text">Although ste&#173;roid agents are not used for primary treatment of PDR, they do reduce PDR-&#173;related outcomes in diabetic eyes. Combined rates of vitreous hemorrhage, need for PRP, and development of neovascularization, as viewed on fundus photo&#173;graphs or during a clinical examination, are reduced in eyes receiving intravitreal ste&#173;roid therapy for non-&#173;PDR indications, such as DME.</p>
			<p class="h3 ParaOverride-13">Surgical management of proliferative diabetic retinopathy</p>
			<p class="h4-text-h3"><span class="h4-head">&#173;Laser surgery</span> Over the past 4 de&#173;cades, &#173;until the recent advent of anti-&#173;VEGF therapy, the mainstay of treatment for PDR was thermal &#173;laser photocoagulation in a panret&#173;i&#173;nal pattern to induce regression of neovascularization. Treatment indications are still largely based on findings from the Diabetic Retinopathy Study (DRS) (<span class="xref-sidebar">Clinical Trial 5-</span>&#173;<span class="xref-sidebar">4</span>). For patients with high-&#173;risk PDR, PRP treatment in eyes not already receiving anti-VEGF therapy is almost always recommended. PRP destroys ischemic ret&#173;ina, which produces growth &#173;factors, such as VEGF, that promote disease progression. PRP also increases oxygen tension in the eye via 2 mechanisms: (1) decreasing oxygen consumption overall as a result of the purposeful ret&#173;i&#173;nal destruction, and (2) increasing the diffusion of oxygen from the choroid in the areas of the photocoagulation scars. Collectively, &#173;these changes result in the regression of existing neovascular tissue and prevent progressive neovascularization.</p>
			<p class="body-text">Treatment may be accomplished in a single session or over multiple sessions. The <a href="http://DRCR.net"><span class="Hyperlink">DRCR.net</span></a> found no long-&#173;term vision benefit of multiple-&#173;session over single-&#173;session &#173;laser administration. &#173;After the initial PRP, additional therapy can be applied incrementally in an attempt to achieve complete regression of per&#173;sis&#173;tent or recurrent neovascularization. Some clinicians combine anti-&#173;VEGF therapy with PRP with the rationale that initial anti-&#173;VEGF therapy &#173;will regress neovascularization quickly, whereas the effect of the PRP &#173;will endure over subsequent years, without the need for long-&#173;term intravitreal injections.</p>
			<p class="body-text">Full PRP, as used in the DRS (see Clinical Trial 5-4) and ETDRS (see Clinical Trial&#160;5-3), included 1200 or more 500-&#173;µm burns using argon green or blue-&#173;green &#173;lasers, separated from each other by one-&#173;half burn width (<span class="xref-figure">Fig 5-</span>&#173;<span class="xref-figure">8</span>). The use of automated pattern scan &#173;laser systems has been increasing in recent years; however, uncontrolled studies have suggested that pattern scan &#173;laser treatments may not be equivalent in their treatment effect on a burn-&#173;for-&#173;burn comparison; the burn-&#173;count target for equivalent treatment effect with pattern scan &#173;laser treatment may need to be higher.</p>
			<p class="body-text">Adverse effects of scatter PRP include choroidal detachment as well as decreases in night vision, color vision, contrast sensitivity, peripheral vision, and, in rare cases, pupillary dilation. Some patients may experience a transient loss of 1 or 2 lines of visual acuity or increased glare following treatment. Other transient adverse effects include loss of accommodation, loss of corneal sensitivity, and photopsias. Macular edema may also be precipitated or worsened by PRP. Sparing the horizontal meridians, that is, the path of the long ciliary vessels and nerves, protects accommodation pupillary function and corneal innervation. Heavy treatment, when necessary, should be performed in areas of the ret&#173;ina where vision loss is less noticed by patients or in areas that are associated with lower rates of morbidity. &#173;Great care must be taken to avoid foveal photocoagulation, especially when using image-&#173;inverting lenses.</p>
			<p class="reference--journal--first">Aiello LP, Avery RL, Arrigg PG, et&#160;al. Vascular endothelial growth &#173;factor in ocular fluid of patients with diabetic retinopathy and other ret&#173;i&#173;nal disorders. <span class="italic">N Engl J Med.</span> 1994;331(22): 1480–1487.</p>
			<p class="reference--journal--mid">Chew EY, Ferris FL III, Csaky KG, et&#160;al. The long-&#173;term effects of &#173;laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. <span class="italic">Ophthalmology.</span> 2003; 110(9):1683–1689.</p>
			<p class="reference--journal--mid">Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. <span class="italic">Ophthalmology.</span> 1981;88(7):583–600.</p>
			<p class="reference--journal--mid">Gross JG, Glassman AR, Jampol LM, et&#160;al; Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panret&#173;i&#173;nal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. <span class="italic">JAMA</span>. 2015;314(20): 2137–2146.</p>
			<p class="reference--journal--mid">Silva PS, Cavallerano JD, Sun JK, et&#160;al. Proliferative diabetic retinopathy. In: Schachat AP, Wilkinson CP, Hinton DR, Sadda SR, Wiedemann P, eds. <span class="italic">Ryan’s Ret&#173;i&#173;na.</span> 6th&#160;ed. Philadelphia: Elsevier/Saunders; 2018:1091–1121.</p>
			<p class="h3 ParaOverride-12">Management of neovascularization of the iris or anterior chamber &#173;angle</p>
			<p class="body-text--no-indent-">Small, isolated tufts of neovascularization at the pupillary border are relatively common in eyes of patients with diabetes mellitus. Treatment can be withheld in eyes with &#173;these tufts in &#173;favor of careful monitoring, with relatively short intervals between slit-&#173;lamp and gonioscopic examinations. Treatment should be considered for eyes that have contiguous neovascularization of the pupil and iris collarette, with or without inclusion of the anterior chamber &#173;angle, and if wide-&#173;field FA reveals widespread nonperfusion or peripheral neovascularization. Treatment usually consists of PRP; intravitreal injection of anti-&#173;VEGF drugs can be used as a temporizing mea&#173;sure to reduce neovascularization &#173;until definitive PRP is administered.</p>
			<p class="h3">Vitrectomy surgery for complications of diabetic retinopathy</p>
			<p class="body-text--no-indent-">Indications for pars plana vitrectomy in patients with PDR are</p>
			<ul>
				<li class="bullet-list-first ParaOverride-14">nonclearing vitreous hemorrhage</li>
				<li class="bullet-list-mid">significant recurring vitreous hemorrhage, despite use of maximal PRP</li>
				<li class="bullet-list-mid">dense premacular subhyaloid hemorrhage</li>
				<li class="bullet-list-mid">tractional ret&#173;i&#173;nal detachment involving or threatening the macula</li>
				<li class="bullet-list-mid">combined tractional and rhegmatogenous ret&#173;i&#173;nal detachment</li>
				<li class="bullet-list-mid">red blood cell–&#173;induced (erythroclastic) glaucoma and “ghost cell” glaucoma</li>
				<li class="bullet-list-mid">anterior segment neovascularization with media opacities preventing PRP</li>
			</ul>
			<p class="h3 ParaOverride-12">Vitreous hemorrhage</p>
			<p class="body-text--no-indent-">The Diabetic Retinopathy Vitrectomy Study (DRVS) was an early prospective, randomized clinical trial that investigated the role of vitrectomy in the management of eyes with severe PDR. Benefits of early (1–6 months &#173;after onset of vitreous hemorrhage) versus late (1 year &#173;after onset) vitrectomy &#173;were evaluated. Eyes of patients with type 1 diabetes mellitus and severe vitreous hemorrhage clearly demonstrated a benefit from earlier vitrectomy, whereas eyes of patients with type 2 or mixed diabetes did not.</p>
			<p class="body-text">If PRP has not been performed previously, earlier intervention is usually recommended. Patients with previous, well-&#173;placed, complete PRP who have vitreous hemorrhage secondary to PDR may be observed for a longer period prior to initiating intervention. Frequent echography (ultrasound) studies are necessary to monitor for ret&#173;i&#173;nal detachment in patients with dense, nonclearing vitreous hemorrhages. If a ret&#173;i&#173;nal detachment is discovered, the timing for the vitrectomy depends upon the characteristics of the detachment. Patients with bilateral severe vitreous hemorrhage should undergo vitrectomy in 1&#160;eye as soon as pos&#173;si&#173;ble for vision rehabilitation. Recent advances in vitreoret&#173;i&#173;nal surgery, including smaller-&#173;gauge instrumentation facilitating faster operating times and fewer complications, have led to earlier intervention for nonclearing vitreous hemorrhage.</p>
			<p class="reference--journal--first ParaOverride-15">Recchia FM, Scott IU, Brown GC, Brown MM, Ho AC, Ip MS. Small-&#173;gauge pars plana vitrectomy: a report by the American Acad&#173;emy of Ophthalmology. <span class="italic">Ophthalmology.</span> 2010;<br />117(9):1851–1857.</p>
			<p class="reference--journal--mid">Simunovic MP, Maberley DA. Anti-&#173;vascular endothelial growth &#173;factor therapy for proliferative diabetic retinopathy: a systematic review and meta-&#173;analysis. <span class="italic">Ret&#173;i&#173;na</span>. 2015;35(10):<br />1931–1942.</p>
			<p class="h3">Tractional ret&#173;i&#173;nal detachment</p>
			<p class="body-text--no-indent-">Complications from PDR may be exacerbated by vitreous attachment to and traction on fibrovascular proliferative tissue, often causing secondary tractional ret&#173;i&#173;nal detachments. Partial posterior vitreous detachment frequently develops in eyes with fibrovascular proliferation, resulting in traction on the new vessels and vitreous or preret&#173;i&#173;nal hemorrhage. Tractional complications such as vitreous hemorrhage, ret&#173;i&#173;nal schisis, ret&#173;i&#173;nal detachment, or macular heterotopia may ensue, as well as progressive fibrovascular proliferation. Contraction of the fibrovascular proliferation and vitreous may result in ret&#173;i&#173;nal breaks and subsequent combined tractional and rhegmatogenous ret&#173;i&#173;nal detachment. The presence of chronic ret&#173;i&#173;nal detachment in eyes with PDR contributes to ret&#173;i&#173;nal is&#173;chemia and may account for the increased risk of anterior segment neovascularization in such eyes.</p>
			<p class="body-text">Tractional ret&#173;i&#173;nal detachment that does not involve the macula may remain stable for many years. When the macula becomes involved or is threatened, prompt vitrectomy is generally recommended. Combined tractional and rhegmatogenous ret&#173;i&#173;nal detachment may pro&#173;gress rapidly; urgent surgery should be considered for &#173;these patients.</p>
			<p class="body-text">A more extensive discussion of the surgical management of tractional ret&#173;i&#173;nal detachments secondary to PDR appears in <span class="xref-local">the section</span> Vitrectomy for Complications of Diabetic Retinopathy in Chapter&#160;20 of this volume.</p>
			</div>
			<p class="h1">Diabetic Macular Edema</p>
			<div id="Chapt5_Top9">
			<p class="body-text--no-indent-">DME results from a hyperglycemia-&#173;induced breakdown of the blood–&#173;retina barrier, which leads to fluid extravasation from ret&#173;i&#173;nal vessels into the surrounding neural ret&#173;ina (<span class="xref-figure">Fig 5-</span>&#173;<span class="xref-figure">9</span>). A diagnosis of DME is made when ret&#173;i&#173;nal thickening that involves the macula is pres&#173;ent. DME may be associated with hard exudates, which are precipitates of plasma lipoproteins. Central subfield–&#173;involved DME that affects the fovea is a common cause of vision loss in diabetic patients. In contrast, non–&#173;center-&#173;involved DME is unlikely to affect vision &#173;unless it progresses to center involvement. Although DME is increasingly common among eyes with more advanced diabetic retinopathy, DME can be pres&#173;ent in any severity level of diabetic retinopathy. Even eyes with mild NPDR can have substantial vision loss from highly thickened ret&#173;i&#173;nas.</p>
			<p class="body-text">FA is useful in demonstrating the breakdown of the blood–&#173;retina barrier by showing local areas of ret&#173;i&#173;nal capillary leakage. However, leakage shown on the angiogram may occur in the absence of macular ret&#173;i&#173;nal thickening and is thus not considered macular edema. Examination with OCT or slit-&#173;lamp biomicroscopy are the most appropriate methods to evaluate eyes for the presence or absence of macular thickening.</p>
			<p class="h2">Classification of Diabetic Macular Edema</p>
			<p class="body-text--no-indent-">Current algorithms for pharmacologic intervention in DME use a &#173;simple, OCT-&#173;based definition to classify DME as <span class="italic">center-&#173;involved</span> or <span class="italic">non–&#173;center-&#173;involved</span>. In <span class="italic">center-&#173;involved DME,</span> the central ret&#173;i&#173;nal subfield appears thickened on OCT scans. DME that does not affect the central subfield is termed <span class="italic">non–&#173;center-&#173;involved</span> (Fig 5–10; Activity 5-1).</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer003" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="activity-first-verso ParaOverride-16">  <span class="QR-code-activity-number">ACTIVITY 5-1</span> OCT Activity: OCT of diabetic macular edema.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer005" class="_idGenObjectStyleOverride-1">
					<div id="_idContainer004" class="_idGenObjectStyleOverride-1">
						<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
					</div>
				</div>
			</div>
			<p class="activity-source-verso ParaOverride-17">Courtesy of Colin A. McCannel, MD.</p>
			<p class="activity-last-verso ParaOverride-18">Access all Section 12 activities at <a href="http://www.aao.org/bcscactivity_section12">www.aao.org/bcscactivity_section12</a>.</p>
			<p class="body-text">The ETDRS was the first prospective, randomized clinical trial of photocoagulation in diabetic patients with less than high-&#173;risk PDR in order to establish standard treatment paradigms for managing DME (see Clinical Trial 5-&#173;3). It defined <span class="italic">clinically significant diabetic macular edema</span> <span class="italic">(CSME)</span> as the indication for focal &#173;laser photocoagulation treatment in the following settings:</p>
			<ul>
				<li class="bullet-list-first">ret&#173;i&#173;nal thickening located at or within 500 µm of the center of the macula</li>
				<li class="bullet-list-mid">hard exudates at or within 500 µm of the center if associated with thickening of adjacent ret&#173;i&#173;na</li>
				<li class="bullet-list-last">a zone of thickening larger than 1 disc area, if located within 1 disc dia&#173;meter of the center of the macula</li>
			</ul>
			<p class="body-text--no-indent-">CSME is an older term that predates diagnoses made with OCT technology. Now that anti-&#173;VEGF treatment has supplanted macular &#173;laser photocoagulation as the first-&#173;line therapy for DME, the CSME diagnosis, which is made clinically, is much less frequently used.</p>
			<p class="body-text">Regardless of &#173;whether it is center-&#173;involved or non–&#173;center-&#173;involved, DME may manifest as focal or diffuse ret&#173;i&#173;nal thickening. <span class="italic">Focal macular edema</span> is characterized by areas of local fluorescein leakage from specific capillary lesions, such as microaneurysms (<span class="xref-figure">Fig&#160;5-&#173;</span><span class="xref-figure">11A</span>). <span class="italic">Diffuse macular edema</span> is characterized by extensive ret&#173;i&#173;nal capillary leakage and widespread breakdown of the blood–&#173;retina barrier, often accumulating in a cystoid configuration in the perifoveal macula (cystoid macular edema) (<span class="xref-figure">Fig 5-11B</span>). Studies have not demonstrated any difference in treatment response corresponding to the pattern of macular edema, &#173;whether focal, diffuse, or a combination of &#173;these.</p>
			<p class="h2">Treatment of Diabetic Macular Edema</p>
			<p class="body-text--no-indent-">In parallel with medical management and optimizing the health habits of the patient, ocular therapies should be considered to maximize visual function and prevent progressive vision loss. &#173;These therapies include ocular pharmacologic management and &#173;laser photocoagulation treatment. Treatment is typically indicated when the macular edema is center-&#173;involved and affects visual acuity. For patients with DME who are asymptomatic or have normal visual acuity, the decision-&#173;making pro&#173;cess for treatment is more complex. &#173;Factors that should be considered include the proximity of exudates or thickening to the fovea, the status and course of the fellow eye, any anticipated cataract surgery, the presence of high-&#173;risk PDR, treatment risks, and any systemic conditions or medi&#173;cations (such as thiazolidinediones) that might exacerbate or cause DME. It is preferable to initiate DME treatment before performing scatter photocoagulation and prior to cataract surgery to reduce the risk of DME resulting from &#173;these interventions.</p>
			<p class="h3 ParaOverride-13">Ocular pharmacologic management of diabetic macular edema</p>
			<p class="body-text--no-indent-">As mentioned, anti-&#173;VEGF drugs are now the first-&#173;line therapy for most eyes with center-&#173;involved DME, especially &#173;those with vision impairment caused by the DME. Corticosteroids are also useful as alternative agents for eyes that are not candidates for anti-&#173;VEGF therapy or that &#173;were incompletely responsive to previous anti-&#173;VEGF treatment.</p>
			<p class="h4-text ParaOverride-4"><span class="h4-head">Anti-&#173;VEGF drugs</span> Currently available anti-&#173;VEGF drugs include aflibercept, bevacizumab, pegaptanib, and ranibizumab. Clinical &#173;trials have demonstrated that all of &#173;these medi&#173;cations are beneficial for eyes with DME. The <a href="http://DRCR.net">DRCR.net</a> Protocol I was the first phase 3 trial to demonstrate that intravitreal anti-&#173;VEGF therapy provides superior visual acuity outcomes as compared to &#173;laser treatment for center-&#173;involved DME. This study revealed that intravitreal ranibizumab combined with prompt or deferred (<span class="symbol">≥</span>24 weeks) focal or grid-&#173;pattern &#173;laser treatment was more effective at both 1-&#173; and 2-&#173;year follow-up in increasing visual acuity than was focal/grid &#173;laser treatment alone or in combination with triamcinolone acetonide injections for the treatment of center-&#173;involved DME. &#173;After 1 year of treatment, eyes in the ranibizumab-&#173;treated groups gained on average 8–9 letters of visual acuity versus &#173;those in the &#173;laser monotherapy group, which gained an average of only 3&#160;letters. Through 5 total years of follow-up, despite the number of injections given progressively decreasing, eyes in the ranibizumab treatment groups maintained the vision gains accrued in the first year of therapy (<span class="xref-figure">Fig 5</span>-&#173;<span class="xref-figure">12</span>). Results from this study also suggest that adding focal-&#173; or grid-&#173;pattern &#173;laser treatment at the initiation of intravitreal ranibizumab for DME is no better, and is possibly worse, for vision outcomes than deferring &#173;laser treatment for 24 weeks or more. Two additional parallel phase 3 &#173;trials, RISE and RIDE (identical study designs, both titled Ranibizumab Injection in Subjects With CSME With Center Involvement Secondary to Diabetes Mellitus) indicated that ranibizumab rapidly and sustainably improves vision, reduces the risk of further vision loss, and improves macular edema in patients with DME, with low rates of complications. At 36 months, the pooled data of &#173;these studies showed that the proportion of patients who gained 15 or more letters of visual acuity from baseline in the 0.3&#160;mg and 0.5&#160;mg ranibizumab-&#173;treated groups &#173;were 41% and 44%, respectively.</p>
			<p class="body-text">Phase 3 &#173;trials have also demonstrated excellent efficacy of aflibercept treatment for DME. &#173;After an initial phase of 5 monthly injections, &#173;after 148 weeks, groups undergoing therapy with aflibercept, both monthly and every 2 months, had substantial visual acuity gains compared with &#173;laser photocoagulation in both the VIVID (Intravitreal Aflibercept Injection in Vision Impairment Due to DME) and VISTA (Study of Intravitreal Aflibercept Injection in Patients With Diabetic Macular Edema) &#173;trials.</p>
			<p class="body-text">Although all of the available anti-&#173;VEGF agents are effective in the treatment of DME, results from the <a href="http://DRCR.net">DRCR.net</a> Protocol T study, which compared the effectiveness of&#160;aflibercept, bevacizumab, and ranibizumab for the treatment of DME, demonstrated the superiority of aflibercept over bevacizumab in improving ETDRS visual acuity gains &#173;after both 1&#160;and 2&#160;years of treatment. Aflibercept was also superior to ranibizumab at 1 year follow-up, but statistically similar at 2&#160;years. The differences between the agents &#173;were due primarily to the effects of &#173;these agents in eyes with worse (<span class="symbol">≤</span>20/50) baseline vision. In eyes with milder visual impairment (20/32 to 20/40), visual results &#173;were equivalent at both 1&#160;and 2&#160;years for all 3 treatment groups. At 2&#160;years, rates of 10 or more letter visual acuity improvement in the aflibercept, bevacizumab, and ranibizumab groups &#173;were 50%, 41%, and 46%, respectively. In contrast, in eyes with worse visual impairment, 2-&#173;year rates of 10 or more letter improvement for the aflibercept, bevacizumab, and ranibizumab groups &#173;were 76%, 66%, and 71%, respectively. Rates of substantial vision loss &#173;were low in all 3&#160;treatment groups.</p>
			<p class="body-text">In general, anti-&#173;VEGF agents are well tolerated. Associated adverse events are most commonly due to the intravitreal injection procedure rather than the medi&#173;cation. Serious intraocular events such as endophthalmitis are rare, with a prevalence of approximately 1&#160;in 1000 injections. Systemic thromboembolic events are known to be associated with systemic anti-&#173;VEGF administration, but have not been shown to be more common among patients who receive intraocular anti-&#173;VEGF treatment. Combined rates of nonfatal myo&#173;car&#173;dial infarction, nonfatal stroke, and vascular death &#173;were higher in the Protocol T patients treated with ranibizumab than the patients treated with the other 2 agents, but extensive analyses of adverse events across other studies have not demonstrated consistent differences in intraocular or systemic safety between the anti-&#173;VEGF agents.</p>
			<p class="h4-text ParaOverride-9"><span class="h4-head">Corticosteroids</span> Use of intravitreal triamcinolone acetonide in patients with refractory DME has been reported to have beneficial effects in a number of small studies. However, at 2&#160;years into the <a href="http://DRCR.net">DRCR.net</a> Protocol B trial, treatment with focal-&#173; or grid-&#173;pattern photocoagulation was found to be more effective, with fewer adverse effects, than treatment with 1-mg or 4-mg doses of preservative-&#173;free intravitreal triamcinolone. <a href="http://DRCR.net">DRCR.&#173;net</a> Protocol I also showed that at 2&#160;years, treatment with intravitreal triamcinolone acetonide in combination with &#173;laser therapy was inferior to treatment with ranibizumab with or without &#173;laser therapy, as well as to &#173;laser treatment alone.</p>
			<p class="body-text">However, results from steroid-&#173;treated eyes that &#173;were pseudophakic at baseline, which therefore did not develop cataracts as a result of ste&#173;roid treatment, &#173;were similar to &#173;those from anti-&#173;VEGF treated eyes and superior to the laser-&#173;treated group. Thus, ste&#173;roid treatment may be a reasonable alternative to anti-&#173;VEGF in eyes with DME that have already under&#173;gone cataract surgery. Studies of 2 types of sustained-&#173;release ste&#173;roid implants, made of dexamethasone and fluocinolone acetonide, respectively, have also demonstrated improved rates of 3 or more lines visual acuity gain with &#173;these agents. Nonetheless, &#173;because of the higher rates of cataract and glaucoma development in steroid-&#173;treated eyes, corticosteroids are usually considered second-&#173;line agents for the treatment of DME. They can be a useful alternative for eyes that are not candidates for anti-&#173;VEGF therapy or that have been refractory despite previous anti-&#173;VEGF treatment. The <a href="http://DRCR.net">DRCR.net</a> Protocol U study, which evaluated eyes with persistent center-involved DME and visual impairment despite at least 6 prior injections of anti-VEGF agents, demonstrated that combination therapy with continued anti-VEGF treatment and a dexamethasone implant did not provide superior vision gains when compared to continued anti-VEGF treatment alone. However, eyes in the combination group did show greater improvements in retinal thickening over the 6-month study period.</p>
			<p class="reference--journal--first">Boyer DS, Yoon YH, Belfort R Jr, et&#160;al; Ozurdex MEAD Study Group. Three-&#173;year, randomized, sham-&#173;controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. <span class="italic">Ophthalmology</span>. 2014;121(10):1904–1914.</p>
			<p class="reference--journal--mid">Campochiaro PA, Brown DM, Pearson A, et&#160;al; FAME Study Group. Long-&#173;term benefit of sustained-&#173;delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. <span class="italic">Ophthalmology</span>. 2011;118(4):626–635.</p>
			<p class="reference--journal--mid">Elman MJ, Aiello LP, Beck RW, et&#160;al; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred &#173;laser or triamcinolone plus prompt &#173;laser for diabetic macular edema. <span class="italic">Ophthalmology.</span> 2010;117(6):1064–1077.</p>
			<p class="reference--journal--mid">Elman MJ, Ayala A, Bressler NM, et&#160;al; Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred &#173;laser treatment: 5-&#173;year randomized trial results. <span class="italic">Ophthalmology.</span> 2015;122(2):375–381.</p>
			<p class="reference--journal--mid">Wells JA, Glassman AR, Ayala AR, et&#160;al; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. <span class="italic">N Engl J Med.</span> 2015;372(13):1193–1203.</p>
			<p class="h3 ParaOverride-19">Surgical management of diabetic macular edema</p>
			<p class="body-text--no-indent-">Focal-&#173; or grid-&#173;pattern macular &#173;laser photocoagulation still has an impor&#173;tant role as an adjunctive treatment in eyes that are resistant to anti-&#173;VEGF agents; it is also appropriate as occasional first-&#173;line treatment in eyes with DME from clearly focal leakage that can be easily targeted by the &#173;laser. In addition, &#173;laser therapy may be a useful first-&#173;line treatment for patients who are not good candidates for anti-&#173;VEGF therapy &#173;because they are medically unstable or who are unable to adhere to near monthly treatment, especially in the first year. Pars plana vitrectomy is often effective in improving ret&#173;i&#173;nal thickening in eyes with DME, but is not always successful at improving vision. Further, definitive studies are needed to clearly define the role of vitrectomy in DME treatment.</p>
			<p class="h4-text ParaOverride-4"><span class="h4-head">&#173;Laser treatment of DME</span> Although anti-&#173;VEGF therapy has largely supplanted &#173;laser photocoagulation for most cases of DME, &#173;laser treatment remains a well-&#173;proven treatment modality with minimal associated adverse events. In the ETDRS, macular focal-&#173; or grid-&#173;pattern &#173;laser photocoagulation treatment of CSME versus observation reduced the risk of moderate vision loss, increased the chance of vision improvement, and was associated with only minor visual field loss. Eyes with less than CSME showed no treatment benefit over the control group at 2&#160;years. In current clinical practice, treatment of eyes with DME can usually be delayed &#173;until progression of edema threatens the center of the macula.</p>
			<p class="body-text">Potential adverse effects of macular &#173;laser therapy include paracentral scotomas, transient increases of edema and/or decreases in vision, &#173;laser scar expansion, subret&#173;i&#173;nal fibrosis, choroidal neovascularization, and inadvertent foveal burns. However, if the &#173;laser treatment is carefully and appropriately applied, most of &#173;these complications should be avoided. Clinical features associated with poorer visual acuity outcomes &#173;after photocoagulation treatment for DME include the following:</p>
			<ul>
				<li class="bullet-list-first ParaOverride-7">macular ischemia (extensive perifoveal capillary nonperfusion)</li>
				<li class="bullet-list-last ParaOverride-20">hard exudates in the fovea</li>
			</ul>
			<p class="body-text--no-indent-">Fluorescein angiography, along with an OCT thickness map, can be used to guide &#173;laser treatment for DME. The &#173;laser par&#173;ameters typically used include spot sizes of 50–100 µm and burn durations of 0.1 second or less. For focal leakage, direct &#173;laser treatment using green or yellow wavelengths is applied to all leaking microaneurysms between 500 µm and 3000 µm from the center of the macula. For diffuse leakage or zones of capillary nonperfusion in the macula, a light-&#173;intensity grid pattern can be applied. Burns are typically separated by 1 burn width, and a green-&#173; or yellow-&#173;wavelength &#173;laser is used. Treatment should include areas of diffuse leakage more than 500 µm from the center of the macula and 500 µm from the temporal margin of the optic nerve head.</p>
			<p class="body-text">&#173;Laser sessions are typically repeated as often as &#173;every 16 weeks &#173;until ret&#173;i&#173;nal thickening has resolved or all of the leaking microaneurysms have been adequately treated. Some studies have suggested that micropulse, or sub–&#173;threshold intensity burns, may be as effective as standard macular &#173;laser treatment while reducing damage to the ret&#173;i&#173;nal pigment epithelium and outer ret&#173;i&#173;nal layers. Treatment of peripheral nonperfusion as visualized on ultra-&#173;wide-&#173;field FA with scatter photocoagulation does not improve visual acuity or ret&#173;i&#173;nal thickening in eyes with DME.</p>
			<p class="reference--journal--single ParaOverride-4">Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. ETDRS report <br />number 2. <span class="italic">Ophthalmology.</span> 1987;94(7):761–774.</p>
			<p class="h4-text ParaOverride-9"><span class="h4-head">Pars plana vitrectomy for DME</span> Pars plana vitrectomy may be useful for treating DME. If &#173;there is evidence of posterior hyaloidal traction or an associated epiret&#173;i&#173;nal membrane leading to mechanical traction, creation of a posterior vitreous detachment and pos&#173;si&#173;ble ILM or epiret&#173;i&#173;nal membrane peeling can be effective in reducing ret&#173;i&#173;nal thickening. Although the use of vitrectomy as first-&#173;line therapy for treatment of eyes with DME without vitreomacular traction is uncommon in the United States, it is more widely prevalent internationally. Vitrectomy generally improves ret&#173;i&#173;nal thickening in eyes with DME. However, multiple studies have demonstrated inconsistent effects of vitrectomy on visual acuity in eyes with DME, despite consistent improvements in edema. Eyes can experience &#173;either substantial vision gain or vision loss &#173;after vitrectomy. The <a href="http://DRCR.net">DRCR.net</a> Protocol D, which was a prospective observational case series, confirmed that &#173;after vitrectomy, ret&#173;i&#173;nal thickening was reduced in most eyes; however, median visual acuity remained unchanged over the 6-&#173;month follow-up period. As mentioned, the exact role of vitrectomy in the treatment of DME remains to be determined through &#173;future, large-&#173;scale definitive studies.</p>
			<p class="reference--journal--first ParaOverride-9">Haller JA, Qin H, Apte RS, et&#160;al; Diabetic Retinopathy Clinical Research Network Writing Committee. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. <span class="italic">Ophthalmology.</span> 2010;117(6):1087–1093.</p>
			<p class="reference--journal--mid">Jackson TL, Nicod E, Angelis A, Grimaccia F, Pringle E, Kanavos&#160;P. Pars plana vitrectomy for diabetic macular edema: a systematic review, meta-&#173;analysis, and synthesis of safety lterature. <span class="italic">Ret&#173;i&#173;na</span>. 2017; 37(5):886–895.</p>
			</div>
			<p class="h1 ParaOverride-2">Cataract Surgery in Patients With Diabetes Mellitus</p>
			<div id="Chapt5_Top10">
			<p class="body-text--no-indent-">Patients with diabetes mellitus who undergo cataract surgery usually have excellent visual outcomes postoperatively. However, vari&#173;ous studies suggest that both eyes with diabetic retinopathy and DME may worsen in severity &#173;after cataract surgery. In <a href="http://DRCR.net"><span class="Hyperlink">DRCR.net</span></a> Protocol P, patients with NPDR but no history of DME &#173;were found to have a substantial risk of postoperative DME &#173;after cataract surgery. In Protocol Q, which enrolled patients with preexisting DME, only a small percentage of eyes had substantial visual acuity loss or definitive progression in central ret&#173;i&#173;nal thickening. Therefore, in clinical practice, it is common for patients with center-&#173;involved DME who are about to undergo cataract surgery to receive an anti-&#173;VEGF drug injection preoperatively or ste&#173;roid injection perioperatively. In addition, control of systemic &#173;factors should be optimized as much as pos&#173;si&#173;ble prior to surgery.</p>
			<p class="body-text">Patients with severe NPDR or PDR should be considered for scatter photocoagulation before undergoing cataract removal, if the ocular media are sufficiently clear to allow for treatment. If the density of the cataract precludes adequate evaluation of the ret&#173;ina or treatment, prompt postoperative ret&#173;i&#173;nal evaluation and treatment are recommended. In general, all patients with preexisting diabetic retinopathy should be reevaluated &#173;after cataract surgery.</p>
			<p class="body-text">Cataract surgeons should be mindful of the need for &#173;future regular ret&#173;i&#173;nal evaluations and the possibility of &#173;future surgical interventions. They should perform an adequate capsulorrhexis to avoid anterior capsular phimosis, and avoid the use of silicone lenses in diabetic eyes, &#173;because &#173;those lenses may fog with condensation during subsequent vitrectomies. BCSC Section&#160;11, <span class="italic">Lens and Cataract,</span> briefly discusses the considerations the cataract surgeon must take into account in patients with diabetes mellitus.</p>
			<p class="reference--journal--first">Baker CW, Almukhtar T, Bressler NM, et&#160;al.; Diabetic Retinopathy Clinical Research Network Authors/Writing Committee. Macular edema &#173;after cataract surgery in eyes without preoperative central-&#173;involved diabetic macular edema. <span class="italic">JAMA Ophthalmol.</span> 2013;131(7):<br />870–879.</p>
			<p class="reference--journal--mid">Bressler SB, Baker CW, Almukhtar T, et&#160;al; Diabetic Retinopathy Clinical Research Network Authors/Writing Committee. Pi&#173;lot study of individuals with diabetic macular edema undergoing cataract surgery. <span class="italic">JAMA Ophthalmol.</span> 2014;132(2):224–226.</p>
		</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer007" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C05_p091-120-web-resources/image/AAX-9637.png" alt="" />
			</div>
		</div>
		<div id="_idContainer008" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 5-1</span><span class="figure-caption-bold"> </span>Optical coherence tomography angiography (OCTA) images demonstrate macular capillary nonperfusion and vascular tortuosity in diabetic eyes. The foveal avascular zone diameters in these images increase with worsening diabetic retinopathy severity level. <span class="figure-caption-bold">A,&#160;</span>Nondiabetic eye. <span class="figure-caption-bold">B, </span>Mild nonproliferative diabetic retinopathy (NPDR). <span class="figure-caption-bold">C, </span>Moderate NPDR. <span class="figure-caption-bold">D,&#160;</span>Proliferative diabetic retinopathy (PDR). <span class="figure-source-note">(Courtesy of Jennifer K. Sun, MD, MPH.)</span></p>
		</div>
		<div id="_idContainer009" class="Basic-Text-Frame">
			<table id="table001" class="No-Table-Style">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-3" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-4" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _1-BCSC-table-title" colspan="5">
							<p class="table-title"><span class="table-number">&#173;Table&#160;5-1</span> Recommended Eye Examination Schedule for Patients <br />With Diabetes Mellitus</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head">Diabetes Type</p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head" />
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head">Recommended Time of First Eye Examination</p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head" />
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head">Routine Minimum Follow-up Interval</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-7">
						<td class="No-Table-Style _4-BCSC-table-body-first-row">
							<p class="table-body">Type 1</p>
						</td>
						<td class="No-Table-Style _4-BCSC-table-body-first-row" />
						<td class="No-Table-Style _4-BCSC-table-body-first-row">
							<p class="table-body">5&#160;years &#173;after diagnosis</p>
						</td>
						<td class="No-Table-Style _4-BCSC-table-body-first-row" />
						<td class="No-Table-Style _4-BCSC-table-body-first-row">
							<p class="table-body">Annually</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body">Type 2</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body">Upon diagnosis</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body">Annually</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-9">
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-1">
							<p class="table-body">Type 1 or 2 and Pregnancy</p>
						</td>
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-1" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-1">
							<p class="table-body">Soon &#173;after conception and early in first trimester</p>
						</td>
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-1" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-1">
							<p class="table-body">No retinopathy to mild or moderate NPDR: &#173;every 3–12 months</p>
							<p class="table-body">Severe NPDR or worse: &#173;every 1–3&#160;months</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-10">
						<td class="No-Table-Style _8-BCSC-table-note" colspan="5">
							<p class="table-footnote">NPDR <span class="symbol">=</span> nonproliferative diabetic retinopathy.</p>
							<p class="table-footnote ParaOverride-21">Modified from American Acad&#173;emy of Ophthalmology Ret&#173;i&#173;na/Vitreous Panel. Preferred Practice Pattern<span class="superscript CharOverride-2">®</span> Guidelines. <span class="table-source-emphasis">Diabetic Retinopathy.</span> San Francisco: American Acad&#173;emy of Ophthalmology; 2016. Available at <a href="http://www.aao.org/ppp"><span class="Hyperlink">www.aao.org/ppp</span></a>.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer010" class="Basic-Text-Frame">
			<table id="table002" class="No-Table-Style">
				<colgroup>
					<col class="_idGenTableRowColumn-11" />
					<col class="_idGenTableRowColumn-12" />
					<col class="_idGenTableRowColumn-13" />
					<col class="_idGenTableRowColumn-12" />
					<col class="_idGenTableRowColumn-14" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-5">
						<td class="No-Table-Style _1-BCSC-table-title" colspan="5">
							<p class="table-title"><span class="table-number">&#173;Table&#160;5-2</span> Recommended Eye Examination Schedule Based on Diabetic <br />Retinopathy Severity</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head">Diabetic Retinopathy Severity</p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head" />
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head">Presence of Macular Edema</p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head" />
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head">Suggested Follow-up Interval (months)</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-7">
						<td class="No-Table-Style _4-BCSC-table-body-first-row">
							<p class="table-body">Normal or minimal NPDR</p>
						</td>
						<td class="No-Table-Style _4-BCSC-table-body-first-row" />
						<td class="No-Table-Style _4-BCSC-table-body-first-row">
							<p class="table-body">No</p>
						</td>
						<td class="No-Table-Style _4-BCSC-table-body-first-row" />
						<td class="No-Table-Style _4-BCSC-table-body-first-row">
							<p class="table-body ParaOverride-22">12</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body">Mild NPDR</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body">No</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body ParaOverride-22">12</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body">Non-&#173;CI DME</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body ParaOverride-22">4–6</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body">CI DME<span class="table-superscript">a</span></p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body ParaOverride-22">1</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body">Moderate NPDR</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body">No</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body ParaOverride-22">6–12</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body">Non-&#173;CI DME</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body ParaOverride-22">3–6</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body">CI DME<span class="table-superscript">a</span></p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body ParaOverride-22">1</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body">Severe NPDR<span class="table-superscript">b</span></p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body">No</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body ParaOverride-22">4</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body">Non-&#173;CI DME</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body ParaOverride-22">2–4</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body">CI DME<span class="table-superscript">a</span></p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body ParaOverride-22">1</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body">Non–&#173;high-&#173;risk PDR<span class="table-superscript">c</span></p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body">No</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body ParaOverride-22">4</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body">Non-&#173;CI DME</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body ParaOverride-22">2–4</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body">CI DME<span class="table-superscript">a</span></p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body ParaOverride-22">1</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body">High-&#173;risk PDR<span class="table-superscript">c</span></p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body">No</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body ParaOverride-22">4</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body">Non-&#173;CI DME</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body ParaOverride-22">4</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body">CI DME<span class="table-superscript">a</span></p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body ParaOverride-22">1</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body">Inactive/involuted PDR</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body">No</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
							<p class="table-body ParaOverride-22">6–12</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-8">
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body">Non-&#173;CI DME</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1" />
						<td class="No-Table-Style _5-BCSC-table-body CellOverride-1">
							<p class="table-body ParaOverride-22">4</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-1" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-1" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-1">
							<p class="table-body">CI DME<span class="table-superscript">a</span></p>
						</td>
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-1" />
						<td class="No-Table-Style _7-BCSC-table-body-last-row CellOverride-1">
							<p class="table-body ParaOverride-22">1</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-15">
						<td class="No-Table-Style _8-BCSC-table-note" colspan="5">
							<p class="table-footnote ParaOverride-22">CI DME <span class="symbol">=</span> center-&#173;involved diabetic macular edema; non-&#173;CI DME <span class="symbol">=</span> non–&#173;center-&#173;involved diabetic macular edema; NPDR <span class="symbol">=</span> nonproliferative diabetic retinopathy; PDR <span class="symbol">=</span> proliferative diabetic retinopathy.</p>
							<p class="table-footnote"><span class="table-superscript-notes">a</span> Consider intravitreal anti–&#173;vascular endothelial growth &#173;factor injection.</p>
							<p class="table-footnote"><span class="table-superscript-notes">b</span> Consider panret&#173;i&#173;nal scatter &#173;laser surgery.</p>
							<p class="table-footnote"><span class="table-superscript-notes">c</span> Consider panret&#173;i&#173;nal scatter &#173;laser surgery or intravitreal anti–&#173;vascular growth &#173;factor injection.</p>
							<p class="table-source-note">Modified from American Acad&#173;emy of Ophthalmology Ret&#173;i&#173;na/Vitreous Panel. Preferred Practice<span class="superscript CharOverride-2">®</span> Pattern Guidelines. <span class="table-source-emphasis">Diabetic Retinopathy.</span> San Francisco: American Acad&#173;emy of Ophthalmology; 2016. Available at <a href="http://www.aao.org/ppp"><span class="Hyperlink">www.aao.org/ppp</span></a>.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer013">
				<div id="_idContainer011" class="Basic-Graphics-Frame _idGenObjectStyleOverride-2">
				</div>
				<div id="_idContainer012" class="Basic-Text-Frame">
					<p class="sidebar-title">CLINICAL TRIAL 5-1</p>
					<p class="sidebar-h1">Diabetes Control and Complications Trial (DCCT)</p>
					<p class="sidebar-text--no-indent- ParaOverride-23"><span class="sidebar-italic">Study questions:</span></p>
					<p class="sidebar-numbered-list-first">1.&#9;Primary prevention study: &#173;Will intensive control of blood glucose level slow development and subsequent progression of diabetic retinopathy (neuropathy and nephropathy)?</p>
					<p class="sidebar-numbered-list-last">2.&#9;Secondary intervention study: &#173;Will intensive control of blood glucose level slow progression of diabetic retinopathy (neuropathy and nephropathy)?</p>
					<p class="sidebar-text--no-indent- ParaOverride-23"><span class="sidebar-italic">Enrollment:</span></p>
					<p class="sidebar-numbered-list-first">1.&#9;726 patients with type 1 diabetes mellitus (1–5&#160;years’ duration) and no diabetic retinopathy.</p>
					<p class="sidebar-numbered-list-last">2.&#9;715 patients with type 1 diabetes mellitus (1–15&#160;years’ duration) and mild to moderate diabetic retinopathy.</p>
					<p class="sidebar-text--no-indent- ParaOverride-23"><span class="sidebar-italic">Study groups:</span> Intensive control of blood glucose level (multiple daily insulin injections or insulin pump) vs conventional management.</p>
					<p class="sidebar-text--no-indent- ParaOverride-24"><span class="sidebar-italic">Outcome variables:</span> Development of diabetic retinopathy or progression of retinopathy by 3 steps using a modified Airlie House classification scale; neuropathy, nephropathy (albuminuria, microalbuminuria), and cardio&#173;vascular outcomes &#173;were also assessed.</p>
					<p class="sidebar-text--no-indent- ParaOverride-24"><span class="sidebar-italic">Results:</span> In the primary prevention cohort, intensive control reduced the risk of developing retinopathy by 76%, and in the secondary intervention cohort, it slowed progression of retinopathy by 54%. In the 2 cohorts combined, intensive control reduced the risk of clinical neuropathy by 60% and albuminuria (nephropathy) by 54%.</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer016">
				<div id="_idContainer014" class="Basic-Graphics-Frame _idGenObjectStyleOverride-2">
				</div>
				<div id="_idContainer015" class="Basic-Text-Frame">
					<p class="sidebar-title">CLINICAL TRIAL 5-2</p>
					<p class="sidebar-h1">United Kingdom Prospective Diabetes Study (UKPDS)</p>
					<p class="sidebar-text--no-indent- ParaOverride-23"><span class="sidebar-italic">Study questions:</span></p>
					<p class="sidebar-numbered-list-first">1.&#9;&#173;Will intensive control of blood glucose level, in patients with type&#160;2 diabetes mellitus, reduce the risk of microvascular complications of diabetes, including the risk of retinopathy progression?</p>
					<p class="sidebar-numbered-list-last">2.&#9;&#173;Will intensive control of blood pressure, in patients with type 2 diabetes mellitus and elevated blood pressure, reduce the risk of microvascular complications of diabetes, including the risk of retinopathy progression?</p>
					<p class="sidebar-text--no-indent- ParaOverride-23"><span class="sidebar-italic">Enrollment:</span></p>
					<p class="sidebar-numbered-list-first">1.&#9;4209 patients with newly diagnosed type 2 diabetes mellitus.</p>
					<p class="sidebar-numbered-list-last">2.&#9;1148 patients with hypertension and newly diagnosed type 2 diabetes mellitus.</p>
					<p class="sidebar-text--no-indent- ParaOverride-23"><span class="sidebar-italic">Randomization:</span></p>
					<p class="sidebar-numbered-list-first">1.&#9;Patients &#173;were randomly assigned to a conventional policy starting with diet (1138 patients) or to an intensive policy starting with a sulfonylurea—&#173;chlorpropamide (788 patients), glibenclamide (615&#160;patients), or glipizide (170 patients) treatment—or treatment with insulin (1156 patients). If overweight and in the intensive group, patients &#173;were assigned to start treatment with metformin (342 patients).</p>
					<p class="sidebar-numbered-list-last">2.&#9;Patients &#173;were randomly assigned to tight control of blood pressure (400 with angiotensin-&#173;converting enzyme [ACE] inhibitor and 398 with beta blockers) or to less tight control (390 patients).</p>
					<p class="sidebar-text--no-indent- ParaOverride-23"><span class="sidebar-italic">Outcome variables:</span> Development of any of 3 aggregate adverse outcomes and specific retinopathy-&#173;related outcomes (worsening of retinopathy on a modified Airlie House scale, ret&#173;i&#173;nal photocoagulation, vitreous hemorrhage, and worsening of visual acuity).</p>
					<p class="sidebar-text--no-indent- ParaOverride-9"><span class="sidebar-italic">Results:</span></p>
					<p class="sidebar-numbered-list-first">1.&#9;Intensive control of blood glucose level slowed progression of retinopathy and reduced the risk of other microvascular complications of diabetes mellitus. Sulfonylureas did not increase the risk of cardiovascular disease.</p>
					<p class="sidebar-numbered-list-last">2.&#9;Intensive control of blood pressure slowed progression of retinopathy and reduced the risk of other microvascular and macrovascular complications of diabetes mellitus. No clinically or statistically significant difference was found in the comparison of blood pressure lowering with ACE inhibitors versus beta blockers.</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer017" class="Basic-Text-Frame">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer020">
				<div id="_idContainer018" class="Basic-Graphics-Frame _idGenObjectStyleOverride-2">
				</div>
				<div id="_idContainer019" class="Basic-Text-Frame">
					<p class="sidebar-title">CLINICAL TRIAL 5-3</p>
					<p class="sidebar-h1">Early Treatment Diabetic Retinopathy Study (ETDRS)</p>
					<p class="sidebar-text--no-indent- ParaOverride-23"><span class="sidebar-italic">Study questions:</span></p>
					<p class="sidebar-numbered-list-first">1.&#9;Is photocoagulation effective for treating DME?</p>
					<p class="sidebar-numbered-list-mid">2.&#9;Is photocoagulation effective for treating diabetic retinopathy?</p>
					<p class="sidebar-numbered-list-last ParaOverride-25">3.&#9;Is aspirin effective for preventing progression of diabetic <br />retinopathy?</p>
					<p class="sidebar-text--no-indent- ParaOverride-26"><span class="sidebar-italic">Eligibility:</span> Mild nonproliferative diabetic retinopathy through early proliferative diabetic retinopathy, with visual acuity 20/200 or better in each eye.</p>
					<p class="sidebar-text--no-indent- ParaOverride-24"><span class="sidebar-italic">Randomization:</span> 3711 participants: 1 eye randomly assigned to photocoagulation (scatter and/or focal) and 1 eye assigned to no photocoagulation; patients randomly assigned to 650&#160;mg/day aspirin or placebo.</p>
					<p class="sidebar-text--no-indent- ParaOverride-24"><span class="sidebar-italic">Outcome variables:</span> Visual acuity less than 5/200 for at least 4 months; visual acuity worsening by doubling of initial visual &#173;angle (eg, 20/40 to 20/80); retinopathy progression.</p>
					<p class="sidebar-text--no-indent- ParaOverride-12"><span class="sidebar-italic">Macular edema results:</span></p>
					<p class="sidebar-numbered-list-first">1.&#9;Focal photocoagulation for DME decreased risk of moderate vision loss (doubling of initial visual &#173;angle).</p>
					<p class="sidebar-numbered-list-mid">2.&#9;Focal photocoagulation for DME increased chance of moderate vision gain (halving of initial visual &#173;angle).</p>
					<p class="sidebar-numbered-list-last">3.&#9;Focal photocoagulation for DME reduced ret&#173;i&#173;nal thickening.</p>
					<p class="figure-caption ParaOverride-27"><span class="CharOverride-3">(continued)</span></p>
					<p class="sidebar-text--no-indent-"><span class="sidebar-italic">Early scatter photocoagulation results:</span></p>
					<p class="sidebar-numbered-list-first">1.&#9;Early scatter photocoagulation resulted in a small reduction in the risk of severe vision loss (<span class="symbol">&lt;</span>5/200 for at least 4 months).</p>
					<p class="sidebar-numbered-list-mid">2.&#9;Early scatter photocoagulation is not indicated for eyes with mild to moderate diabetic retinopathy.</p>
					<p class="sidebar-numbered-list-last">3.&#9;Early scatter photocoagulation may be most effective in patients with type 2 diabetes mellitus.</p>
					<p class="sidebar-text--no-indent- ParaOverride-23"><span class="sidebar-italic">Aspirin use results:</span></p>
					<p class="sidebar-numbered-list-first">1.&#9;Aspirin use did not alter progression of diabetic retinopathy.</p>
					<p class="sidebar-numbered-list-mid">2.&#9;Aspirin use did not increase risk of vitreous hemorrhage.</p>
					<p class="sidebar-numbered-list-mid">3.&#9;Aspirin use did not affect visual acuity.</p>
					<p class="sidebar-numbered-list-last">4.&#9;Aspirin use reduced risk of cardiovascular morbidity and mortality.</p>
				</div>
			</div>
		</div>
		<div id="_idContainer021" class="Basic-Text-Frame">
			<p class="figure-caption ParaOverride-28"><span class="figure-caption-bold CharOverride-4">(Continued on next page)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer022" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C05_p091-120-web-resources/image/KIN00197.png" alt="" />
			</div>
		</div>
		<div id="_idContainer023" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 5-2</span><span class="figure-caption-bold"> </span>Fundus photograph shows diffuse intraretinal hemorrhages <span class="figure-caption-italic">(arrow) </span>and microaneurysms in an eye with NPDR. <span class="figure-source-note">(Standard photograph 2A, courtesy of the Early Treatment Diabetic Study [ETDRS].)</span></p>
		</div>
		<div id="_idContainer024" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 5-4</span><span class="figure-caption-bold"> </span>Fundus photograph shows intraretinal microvascular abnormalities (IRMAs) <span class="figure-caption-italic">(arrows) </span>in an eye with NPDR. <span class="figure-source-note">(Courtesy of Jennifer K. Sun, MD, MPH.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer026">
				<div id="_idContainer025" class="Basic-Graphics-Frame _idGenObjectStyleOverride-2">
				</div>
			</div>
		</div>
		<div id="_idContainer027" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 5-3</span><span class="figure-caption-bold"> </span>Fundus photograph shows venous beading in an eye with NPDR <span class="figure-caption-italic">(arrows). </span><span class="figure-source-note">(Sta</span><span class="figure-source-note">n</span><span class="figure-source-note">dard photograph 6B, courtesy of the ETDRS.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer028" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C05_p091-120-web-resources/image/AAX-9642.png" alt="" />
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer029" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C05_p091-120-web-resources/image/KIN00198.png" alt="" />
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer030" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C05_p091-120-web-resources/image/KIN00200.png" alt="" />
			</div>
		</div>
		<div id="_idContainer031" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 5-5</span><span class="figure-caption-bold"> </span>Fundus photograph of a left eye demonstrates neovascularization of the disc (NVD, <span class="figure-caption-italic">arro</span><span class="figure-caption-italic">w</span>) with a small amount of vitreous hemorrhage<span class="figure-caption-italic">. </span>Even without vitreous hemor-<br />rhage, this degree of NVD is the lower limit of moderate NVD and is considered high-risk PDR. <span class="figure-source-note">(Standard photograph 10A, courtesy of the Diabetic Retinopathy Study [DRS].)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer032" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C05_p091-120-web-resources/image/AAX-0605.jpg" alt="" />
			</div>
		</div>
		<div id="_idContainer033" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 5-6</span><span class="figure-caption-bold"> </span>Fundus photograph of a right eye shows cotton-wool spots and moderate neovascularization elsewhere (NVE) with preretinal hemorrhage. <span class="figure-source-note">(Standard photograph 7, courtesy of the DRS.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer036">
				<div id="_idContainer034" class="Basic-Graphics-Frame _idGenObjectStyleOverride-2">
				</div>
				<div id="_idContainer035" class="Basic-Text-Frame">
					<p class="sidebar-title">CLINICAL TRIAL 5-4</p>
					<p class="sidebar-h1">Diabetic Retinopathy Study (DRS)</p>
					<p class="sidebar-text--no-indent-"><span class="sidebar-italic">Study question:</span> Is photocoagulation (argon or xenon arc) effective for treating diabetic retinopathy?</p>
					<p class="sidebar-text--no-indent- ParaOverride-24"><span class="sidebar-italic">Eligibility:</span> PDR or bilateral severe NPDR, with visual acuity 20/100 or better in each eye.</p>
					<p class="sidebar-text--no-indent- ParaOverride-24"><span class="sidebar-italic">Randomization:</span> 1742 participants: 1 eye randomly assigned to photocoagulation (argon or xenon arc) and 1 eye assigned to no photocoagulation.</p>
					<p class="sidebar-text--no-indent- ParaOverride-24"><span class="sidebar-italic">Outcome variable:</span> Severe vision loss (SVL), ie, visual acuity less than 5/200 for at least 4 months, at 5&#160;years.</p>
					<p class="sidebar-text--no-indent- ParaOverride-24"><span class="sidebar-italic">Results:</span> At 5&#160;years of follow-up, eyes treated with PRP had a reduction of 50% or more in rates of SVL compared with untreated control eyes. Thus, photocoagulation (argon or xenon) reduces risk of SVL compared with no treatment. Treated eyes with high-&#173;risk PDR achieved the greatest benefit (<span class="xref-figure">Fig 5-7</span>). Complications of argon &#173;laser PRP in the DRS &#173;were generally mild but included a decrease in visual acuity by 1 or more lines in 11% and visual field loss in 5%.</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer039">
				<div id="_idContainer037" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C05_p091-120-web-resources/image/AAX-0501.png" alt="" />
				</div>
				<div id="_idContainer038" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 5-7</span><span class="figure-caption-bold"> </span>Comparison of treated versus control groups in the Diabetic Retinopathy Study shows cumulative percentage of eyes that experienced severe vision loss during the period of follow-up for argon laser and xenon arc treatment groups combined. <span class="figure-source-note">(From Diabetic Retinopathy Study Research Group (DRS). Photocoagulation treatment of proliferative di</span><span class="figure-source-note">a</span><span class="figure-source-note">betic retinopathy. Clinical application of DRS findings. DRS report number 8. </span><span class="figure-source-emphasis">Ophthalmology.</span><span class="figure-source-note"> 1981;88(7):583–600.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer040" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 5-8</span><span class="figure-caption-bold"> </span>Fundus photograph shows an eye that has undergone panretinal photocoagulation (PRP) treatment. Laser scars are characterized by either chorioretinal and retinal pigment epithelium (RPE) atrophy or RPE hyperpigmentation. <span class="figure-source-note">(Courtesy of Jennifer K. Sun, MD, MPH.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer041" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C05_p091-120-web-resources/image/AAX-9643.jpg" alt="" />
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer044">
				<div id="_idContainer042" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C05_p091-120-web-resources/image/AAX-7576.png" alt="" />
				</div>
				<div id="_idContainer043" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 5-9</span><span class="figure-caption-bold"> </span>Diabetic macular edema (DME).<span class="figure-caption-bold"> A, </span>Artist’s rendering of the mechanism of DME, demonstrating development of retinal thickening from a breakdown of the blood–retina barrier. <span class="figure-caption-bold">B, </span>Spectral-domain OCT (SD-OCT) scan of DME. Whereas there are extensive cystic changes in the outer plexiform and outer nuclear layers, the external limiting membrane line appears intact across the extent of the scan, with the exception of shadowing artifacts from more superficial hyperreflective lesions. Note the foveal detachment. <span class="figure-source-note">(Part A from Ginsburg LH, Aiello LM. Diabetic retinopathy: classification, progression, and management. </span><span class="figure-source-emphasis">Focal Points: Clinical Modules for Ophthalmologists. </span><span class="figure-source-note">San Francisco: American Academy of Ophthalmology; 1993, module 7. Illustration by Christine Gralapp. Part B courtesy of Colin A. McCannel, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer045" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C05_p091-120-web-resources/image/KIN00934.png" alt="" />
			</div>
		</div>
		<div id="_idContainer046" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 5-10</span><span class="figure-caption-bold"> </span>OCT volume scan of an eye with DME from a 75-year-old Hispanic male patient with a long history of poorly controlled type 2 diabetes mellitus (A<span class="CharOverride-5">1C</span> levels typically in the 9–9.6 range). The right eye is affected with moderate NPDR. The patient has undergone previous treatment with bevacizumab and aflibercept, but there is persistent center-involved DME. The cystic changes involving the temporal and inferior foveal region are most noticeable in slices 10 through 7 in Activity 5-1. <span class="figure-source-note">(Courtesy of Colin A. McCannel, MD.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer047" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C05_p091-120-web-resources/image/AAX-9644.png" alt="" />
			</div>
		</div>
		<div id="_idContainer048" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 5-11</span><span class="figure-caption-bold"> </span>Imaging of eyes with DME on fundus photography and OCT. <span class="figure-caption-bold">A, </span>Eye with non–center-involved DME. <span class="figure-caption-bold">B, </span>Eye with center-involved DME. <span class="figure-source-note">(Courtesy of Jennifer K. Sun, MD, MPH.) </span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer051">
				<div id="_idContainer049" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S12_C05_p091-120-web-resources/image/AAX-8402.png" alt="" />
				</div>
				<div id="_idContainer050" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 5-12</span><span class="figure-caption-bold"> </span>Results of the Diabetic Retinopathy Clinical Research Network (<a href="http://DRCR.net">DRCR.net</a>) Protocol I through 3 years demonstrating the superior visual acuity outcomes of treatment with ranibizumab, with either prompt or deferred laser treatment, compared with laser alone or in combination with triamcinolone through 2 years. Starting in the third year, only patients originally assigned to the ranibizumab groups were followed up. Results from years 3–5 suggest that treatment with ranibizumab plus prompt laser therapy is no better and is possibly worse than ranibizumab with deferred laser treatment. <span class="figure-source-note">(From Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, Aiello LP, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. </span><span class="figure-source-emphasis">Ophthalmology.</span><span class="figure-source-note"> 2012;119(11):231</span><span class="figure-source-note">2</span><span class="figure-source-note">–2318.) </span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer054">
				<div id="_idContainer052" class="Basic-Graphics-Frame _idGenObjectStyleOverride-2">
				</div>
				<div id="_idContainer053" class="Basic-Text-Frame">
					<p class="sidebar-title ParaOverride-29">Selected Diabetic Retinopathy Clinical Research </p>
					<p class="sidebar-title-copy ParaOverride-30">Network Studies</p>
					<p class="sidebar-text--no-indent-">The Diabetic Retinopathy Clinical Research Network (<a href="http://DRCR.net">DRCR.net</a>) was developed to conduct multicenter clinical research initiatives in diabetic eye disease that involve community practices as well as academic centers. Since its inception in 2002, the <a href="http://DRCR.net">DRCR.&#173;net</a> has conducted many of the studies that have established current standard-&#173;care practices for diabetic retinopathy and DME (&#173;<span class="xref-table CharOverride-6">Table&#160;5-3</span>).</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer057">
				<div id="_idContainer055" class="Basic-Text-Frame">
					<table id="table003" class="No-Table-Style">
						<colgroup>
							<col class="_idGenTableRowColumn-12" />
							<col class="_idGenTableRowColumn-2" />
							<col class="_idGenTableRowColumn-16" />
							<col class="_idGenTableRowColumn-2" />
							<col class="_idGenTableRowColumn-17" />
							<col class="_idGenTableRowColumn-2" />
							<col class="_idGenTableRowColumn-18" />
						</colgroup>
						<tbody>
							<tr class="No-Table-Style _idGenTableRowColumn-19">
								<td class="No-Table-Style _1-BCSC-table-title" colspan="7">
									<p class="table-title"><span class="table-number">&#173;Table&#160;5-3</span> Diabetic Retinopathy Clinical Research Network (<a href="http://DRCR.net"><span class="Hyperlink">DRCR.net</span></a>) Studies</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-6">
								<td class="No-Table-Style _3-BCSC-table-column-head">
									<p class="table-column-head">Protocol</p>
								</td>
								<td class="No-Table-Style _3-BCSC-table-column-head" />
								<td class="No-Table-Style _3-BCSC-table-column-head">
									<p class="table-column-head">Study Name</p>
								</td>
								<td class="No-Table-Style _3-BCSC-table-column-head" />
								<td class="No-Table-Style _3-BCSC-table-column-head">
									<p class="table-column-head">End Date</p>
								</td>
								<td class="No-Table-Style _3-BCSC-table-column-head" />
								<td class="No-Table-Style _3-BCSC-table-column-head">
									<p class="table-column-head">Study Conclusions</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-20">
								<td class="No-Table-Style _4-BCSC-table-body-first-row">
									<p class="table-body">A</p>
								</td>
								<td class="No-Table-Style _4-BCSC-table-body-first-row" />
								<td class="No-Table-Style _4-BCSC-table-body-first-row">
									<p class="table-body">A Pi&#173;lot Study of &#173;Laser Photocoagulation for Diabetic Macular Edema</p>
								</td>
								<td class="No-Table-Style _4-BCSC-table-body-first-row" />
								<td class="No-Table-Style _4-BCSC-table-body-first-row">
									<p class="table-body">01/31/2008</p>
								</td>
								<td class="No-Table-Style _4-BCSC-table-body-first-row" />
								<td class="No-Table-Style _4-BCSC-table-body-first-row">
									<p class="table-body">In eyes with DME, an MMG photocoagulation technique was less effective at reducing OCT-&#173;measured ret&#173;i&#173;nal thickening over 12&#160;months than the standard focal photocoagulation technique modified from the ETDRS.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-21">
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">B</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and &#173;Laser Photocoagulation for Diabetic Macular Edema</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">10/03/2008</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">Over 2&#160;years, focal/grid photocoagulation for center-&#173;involved DME was more effective and had fewer adverse effects than 1-mg or 4-mg doses of preservative-&#173;free intravitreal triamcinolone.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-22">
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">C</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">Temporal Variation in Optical Coherence Tomography Mea&#173;sure&#173;ments of Ret&#173;i&#173;nal Thickening in Diabetic Macular Edema</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">05/20/2005</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">Although ret&#173;i&#173;nal thickening decreases slightly over the day on average, most eyes with DME have &#173;little meaningful change in OCT CST or visual acuity between the hours of 8 <span class="SC">AM</span> and 4 <span class="SC">PM</span>. A&#160;change in CST <span class="symbol">&gt;</span>11% is likely to be real.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-22">
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">D</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">Evaluation of Vitrectomy for Diabetic Macular Edema Study</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">02/26/2009</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">Vitrectomy reduces ret&#173;i&#173;nal thickening in most eyes with DME and vitreomacular traction. Although visual acuity outcomes improved by 10 or more letters in 38% of eyes, 22% lost 10 or more letters &#173;after vitrectomy.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-21">
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">E</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">A Pi&#173;lot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">11/01/2007</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">In cases of DME where the patient has good visual acuity, peribulbar triamcinolone, with or without focal photocoagulation, is unlikely to be of substantial benefit.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-21">
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">F</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">An Observational Study of the Development of Diabetic Macular Edema Following Scatter &#173;Laser Photocoagulation</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">01/31/2008</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">Clinically meaningful differences in OCT thickness or visual acuity are not substantially dif&#173;fer&#173;ent when PRP is applied in 1 sitting compared with 4 sittings.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-23">
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">G</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">Subclinical Diabetic Macular Edema Study</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">04/22/2009</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">Approximately one-&#173;quarter to one-&#173;half of eyes diagnosed with subclinical DME &#173;will pro&#173;gress to more definite thickening or be judged to need treatment for DME within 2&#160;years. &#173;Because CST is greater in men than in &#173;women, studies involving comparisons of ret&#173;i&#173;nal thickness to expected norms should consider dif&#173;fer&#173;ent mean values for men and &#173;women.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-24">
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-2 _idGenCellOverride-1">
									<p class="table-body">H</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-2 _idGenCellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-2 _idGenCellOverride-1">
									<p class="table-body">A Phase 2 Evaluation of Anti-&#173;VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-2 _idGenCellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-2 _idGenCellOverride-1">
									<p class="table-body">02/29/2008</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-2 _idGenCellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-2 _idGenCellOverride-1">
									<p class="table-body">Intravitreal bevacizumab can reduce DME in some eyes, but this preliminary study was not designed to definitively determine &#173;whether the treatment was beneficial.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-19">
								<td class="No-Table-Style _1-BCSC-table-title" colspan="7">
									<p class="table-title"><span class="table-number">&#173;Table&#160;5-3</span> <span class="CharOverride-3">(continued)</span></p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-6">
								<td class="No-Table-Style _3-BCSC-table-column-head">
									<p class="table-column-head">Protocol</p>
								</td>
								<td class="No-Table-Style _3-BCSC-table-column-head" />
								<td class="No-Table-Style _3-BCSC-table-column-head">
									<p class="table-column-head">Study Name</p>
								</td>
								<td class="No-Table-Style _3-BCSC-table-column-head" />
								<td class="No-Table-Style _3-BCSC-table-column-head">
									<p class="table-column-head">End Date</p>
								</td>
								<td class="No-Table-Style _3-BCSC-table-column-head" />
								<td class="No-Table-Style _3-BCSC-table-column-head">
									<p class="table-column-head">Study Conclusions</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-25">
								<td class="No-Table-Style _5-BCSC-table-body-space">
									<p class="table-body">I</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space" />
								<td class="No-Table-Style _5-BCSC-table-body-space">
									<p class="table-body">Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with &#173;Laser Photocoagulation for Diabetic Macular Edema</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space" />
								<td class="No-Table-Style _5-BCSC-table-body-space">
									<p class="table-body">12/31/2013</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space" />
								<td class="No-Table-Style _5-BCSC-table-body-space">
									<p class="table-body">At 2&#160;years, intravitreal ranibizumab with prompt or deferred (<span class="symbol">≥</span>24&#160;weeks) focal/grid &#173;laser photocoagulation is more effective in increasing visual acuity compared with focal/grid &#173;laser treatment alone or intravitreal triamcinolone with &#173;laser photocoagulation for the treatment of center-&#173;involved DME. Focal/grid &#173;laser treatment at the initiation of intravitreal ranibizumab is no better, and possibly worse, for vision outcomes than deferring &#173;laser treatment for 24 weeks or more in eyes with center-&#173;involved DME with vision impairment.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-22">
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">J</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panret&#173;i&#173;nal Photocoagulation for Proliferative Diabetic Retinopathy</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">07/07/2010</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">The addition of 1 intravitreal triamcinolone injection or 2 intravitreal ranibizumab injections in eyes receiving focal/grid &#173;laser photocoagulation for DME and PRP is associated with better visual acuity outcomes and decreased macular edema by 14 weeks.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-22">
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">K</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">The Course of Response to Focal Photocoagulation for Diabetic Macular Edema</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">06/19/2008</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">Eyes that demonstrate a definite reduction in, but not complete resolution of, central DME at 16 weeks &#173;after focal/grid &#173;laser photocoagulation have a 23%–63% likelihood of continuing to improve without additional treatment.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-26">
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">L</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">Evaluation of Visual Acuity Mea&#173;sure&#173;ments in Eyes with Diabetic Macular Edema</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">11/06/2010</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">Across nationwide sites using a variety of autorefractors, visual acuity tended to be worse and more variable with autorefraction than manual refraction, suggesting that autorefraction is not a good substitute for manual refraction for clinical &#173;trials with improved visual acuity outcomes as a primary endpoint.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-22">
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">M</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">Effect of Diabetes Education During Ret&#173;i&#173;nal Ophthalmology Visits on Diabetes Control</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">12/31/2014</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">Use of a personalized intervention at ophthalmology visits, including HbA<span class="subscript _idGenCharOverride-1">1c</span> mea&#173;sure&#173;ment and counseling about the importance of glycemic control in reducing diabetic complications, was not effective in improving HbA<span class="subscript _idGenCharOverride-1">1c</span> levels.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-6">
								<td class="No-Table-Style _3-BCSC-table-column-head">
									<p class="table-column-head">Protocol</p>
								</td>
								<td class="No-Table-Style _3-BCSC-table-column-head" />
								<td class="No-Table-Style _3-BCSC-table-column-head">
									<p class="table-column-head">Study Name</p>
								</td>
								<td class="No-Table-Style _3-BCSC-table-column-head" />
								<td class="No-Table-Style _3-BCSC-table-column-head">
									<p class="table-column-head">End Date</p>
								</td>
								<td class="No-Table-Style _3-BCSC-table-column-head" />
								<td class="No-Table-Style _3-BCSC-table-column-head">
									<p class="table-column-head">Study Conclusions</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-27">
								<td class="No-Table-Style _5-BCSC-table-body-space">
									<p class="table-body">N</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space" />
								<td class="No-Table-Style _5-BCSC-table-body-space">
									<p class="table-body">An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space" />
								<td class="No-Table-Style _5-BCSC-table-body-space">
									<p class="table-body">12/21/2012</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space" />
								<td class="No-Table-Style _5-BCSC-table-body-space">
									<p class="table-body">Intravitreous ranibizumab versus saline did result in significantly dif&#173;fer&#173;ent rates of vitrectomy by 16 weeks in eyes with vitreous hemorrhage from PDR. However, ranibizumab treatment resulted in improved short-&#173;term secondary outcomes including visual acuity improvement, increased panret&#173;i&#173;nal photocoagulation completion rates, and reductions in recurrent vitreous hemorrhage.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-23">
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">O</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">Comparison of Time-&#173;Domain OCT and Spectral-&#173;Domain OCT Ret&#173;i&#173;nal Thickness Mea&#173;sure&#173;ment <br />in Diabetic Macular Edema</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">01/31/2013</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">This study of eyes with no to minimal nonproliferative diabetic retinopathy developed conversion equations to transform CST values obtained on a spectral-&#173;domain OCT to a time-&#173;domain OCT scale for group comparisons. In addition, values &#173;were established for machine and gender-&#173;specific thresholds to determine DME presence in diabetic eyes.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-22">
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">P</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">A Pi&#173;lot Study in Individuals with Center-&#173;Involved DME Undergoing Cataract Surgery</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">11/12/2010</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">This small, observational study of eyes with DME undergoing cataract surgery revealed only a small percentage of eyes experienced substantial visual acuity loss or definitive worsening of DME &#173;after surgery.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-22">
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">Q</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">An Observational Study in Individuals with Diabetic Retinopathy without Center-&#173;Involved DME Undergoing Cataract Surgery</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">05/19/2011</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">A history of DME treatment and presence of non–&#173;center-&#173;involved DME are risk &#173;factors for development of center-&#173;involved DME &#173;after cataract surgery in eyes with diabetic retinopathy and no center-&#173;involved DME prior to surgery.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-21">
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">R</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">A Phase II Evaluation of Topical NSAIDs in Eyes with Non Central Involved DME</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">12/18/2013</p>
								</td>
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1" />
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-1">
									<p class="table-body">At 1-&#173;year follow-up in eyes with non–&#173;center-&#173;involved DME, this study did not identify a difference between the effect of topical nepafenac 0.1% and placebo drops on OCT par&#173;ameters or visual acuity.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-28">
								<td class="No-Table-Style _7-BCSC-table-body-last-row-space CellOverride-1">
									<p class="table-body">S</p>
								</td>
								<td class="No-Table-Style _7-BCSC-table-body-last-row-space CellOverride-1" />
								<td class="No-Table-Style _7-BCSC-table-body-last-row-space CellOverride-1">
									<p class="table-body">Prompt Panret&#173;i&#173;nal Photocoagulation versus Intravitreal Ranibizumab with Deferred Panret&#173;i&#173;nal Photocoagulation for Proliferative Diabetic Retinopathy</p>
								</td>
								<td class="No-Table-Style _7-BCSC-table-body-last-row-space CellOverride-1" />
								<td class="No-Table-Style _7-BCSC-table-body-last-row-space CellOverride-1">
									<p class="table-body ParaOverride-31">—&#173;</p>
								</td>
								<td class="No-Table-Style _7-BCSC-table-body-last-row-space CellOverride-1" />
								<td class="No-Table-Style _7-BCSC-table-body-last-row-space CellOverride-1">
									<p class="table-body">Ranibizumab injections are an effective alternative to panret&#173;i&#173;nal photocoagulation in treating PDR. At 2&#160;years, visual acuity outcomes &#173;were noninferior to ranibizumab, while average visual acuity over the 2-&#173;year period was better and &#173;there was less peripheral field loss, reduced rates of DME onset, and fewer eyes that underwent vitrectomy.</p>
								</td>
							</tr>
							<tr class="No-Table-Style _idGenTableRowColumn-29">
								<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-3" colspan="7">
									<p class="table-body ParaOverride-32"><span class="CharOverride-3">(Continued)</span></p>
								</td>
							</tr>
						</tbody>
					</table>
				</div>
				<div id="_idContainer056" class="Basic-Text-Frame">
					<p class="table-body ParaOverride-32"><span class="CharOverride-3">(Continued)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer060">
				<div id="_idContainer058" class="Basic-Text-Frame">
				</div>
				<div id="_idContainer059" class="Basic-Graphics-Frame _idGenObjectStyleOverride-3">
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer062">
				<div id="_idContainer061" class="Basic-Graphics-Frame _idGenObjectStyleOverride-4">
				</div>
			</div>
		</div>
		<div id="_idContainer063" class="Basic-Text-Frame">
			<table id="table004" class="No-Table-Style">
				<colgroup>
					<col class="_idGenTableRowColumn-12" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-16" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-17" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-18" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-19">
						<td class="No-Table-Style _1-BCSC-table-title" colspan="7">
							<p class="table-title"><span class="table-number">&#173;Table&#160;5-3</span> <span class="CharOverride-3">(continued)</span></p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-6">
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head">Protocol</p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head" />
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head">Study Name</p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head" />
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head">End Date</p>
						</td>
						<td class="No-Table-Style _3-BCSC-table-column-head" />
						<td class="No-Table-Style _3-BCSC-table-column-head">
							<p class="table-column-head">Study Conclusions</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-30">
						<td class="No-Table-Style _5-BCSC-table-body-space">
							<p class="table-body">T</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space" />
						<td class="No-Table-Style _5-BCSC-table-body-space">
							<p class="table-body">A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space" />
						<td class="No-Table-Style _5-BCSC-table-body-space">
							<p class="table-body">10/18/2018</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space" />
						<td class="No-Table-Style _5-BCSC-table-body-space">
							<p class="table-body">The 2-&#173;year clinical trial compared 3 drugs used to treat DME and found that gains in vision &#173;were greater for participants receiving the drug aflibercept than for &#173;those receiving bevacizumab, but only among participants starting treatment with 20/50 or worse visual acuity. At 1 year, aflibercept had superior gains to ranibizumab in this vision subgroup; however, a difference could not be identified at 2&#160;years. The 3 drugs yielded similar gains in vision for patients with 20/32 or 20/40 visual acuity at the start of treatment.</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-31">
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-4">
							<p class="table-body">U</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-4">
							<p class="table-body">Short-&#173;term Evaluation of Combination Corticosteroid <span class="symbol">+</span> Anti-&#173;VEGF Treatment for Per&#173;sis&#173;tent Central-&#173;Involved Diabetic Macular Edema Following Anti-&#173;VEGF Therapy</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-4">
							<p class="table-body">6/01/2017</p>
						</td>
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-4" />
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-4">
							<p class="table-body">In eyes with per&#173;sis&#173;tent DME and visual impairment despite previous anti-&#173;VEGF therapy, the dexamethasone <span class="symbol">+</span> ranibizumab group experienced greater reduction of DME but no greater improvement in vision than the sham <span class="symbol">+</span> ranbizumab group over 6 months.</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-22">
						<td class="No-Table-Style _5-BCSC-table-body-space CellOverride-5" colspan="7">
							<p class="table-footnote ParaOverride-22">CST <span class="symbol">=</span> central subfield thickness; DME <span class="symbol">=</span> diabetic macular edema; ETDRS <span class="symbol">=</span> Early Treatment Diabetic Retinopathy Study; HbA<span class="subscript _idGenCharOverride-1">1c</span> <span class="symbol">=</span> hemoglobin A<span class="subscript _idGenCharOverride-1">1c</span>; MMG <span class="symbol">=</span> modified macular grid; OCT <span class="symbol">=</span> optical coherence tomography; PDR <span class="symbol">=</span> proliferative diabetic retinopathy.</p>
							<p class="table-footnote ParaOverride-33">Data from Diabetic Retinopathy Clinical Research Network (<a href="http://DRCR.net">DRCR.net</a>) website; <a href="http://www.drcr.net">www.drcr.net</a>. Accessed March 15, 2018.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
	</body>
</html>
